Top ▲
Ligand name | ID | Synonyms | |||||||
A | Back to top | ||||||||
852A | 9025 | ||||||||
A286982 | 6592 | A 286982, A-286982 | |||||||
A438079 | 4118 | A 438079, A-438079 | |||||||
AB928 | 11154 | AB-928 | |||||||
abatacept | 6891 | BMS-188667, CTLA4-IgG4m, Orencia®, RG-1046, RG-2077 | |||||||
ABBV-3373 | 12917 | ADC 122 | |||||||
abediterol | 9326 | LAS-100977 | |||||||
AbGn-168H | 10013 | AbGn-168, neihulizumab | |||||||
abrezekimab | 9806 | CDP7766, UCB-4144, UCB4144, VR-942 | |||||||
abrilumab | 11531 | AMG 181, AMG-181, MEDI-7183, MEDI7183 | |||||||
abrocitinib | 9991 | Cibinqo®, compound 25 [PMID: 29298069], PF-04965842, PF04965842 | |||||||
abscisic acid | 10362 | (+/-)-(cis,trans)-abscisic acid, (+/-)-Abscisic acid, (RS)-Abscisic acid, ABA | |||||||
ABT-737 | 8320 | ABT 737, ABT737, compound 2 [PMID 17256834] | |||||||
AC430 | 9177 | AC-430 | |||||||
acalabrutinib | 8912 | ACP-196, Calquence®, Example 6 [US20140155385 A1] | |||||||
Ac-SDKP | 10060 | goralatide, seraspenide | |||||||
ACT-1014-6470 | 12326 | example 172 [WO2019137927A1], Ic-58 | |||||||
ACT-389949 | 9511 | ||||||||
ACT-660602 | 12207 | ACT660602, compound 9j [PMID: 35947786] | |||||||
ACT-777991 | 12584 | ACT777991, compound 8a [PMID: 36883854] | |||||||
ACTH | 3633 | Acthar®, adrenocorticotropic hormone (1-39), corticotropin | |||||||
acumapimod | 9203 | BCT 197, BCT-197, BCT197, compound A [WO2013139809] | |||||||
adalimumab | 4860 | D2E7, Humira® | |||||||
(-)-adrenaline | 479 | adrenalin, Auvi-Q®, Epipen®, l-adrenaline, L-epinephrine, levoepinephrine | |||||||
adrenomedullin | 683 | AM | |||||||
adriforant | 8985 | PF 3893787, PF-03893787, ZPL-389, ZPL-3893787, ZPL389, ZPL3893787 | |||||||
ADU-S100 | 10192 | dithio-(Rp,Rp)-[cyclic[A(2',5')pA(3',5')p]], MIW815, ML RR-S2 CDA, S100 | |||||||
AF12198 | 4861 | AF 12198, AF-12198 | |||||||
AFM13 | 10067 | AFM 13, AFM-13 | |||||||
agatolimod | 9843 | CpG 7909, CpG7909, PF 3512676, PF-3512676, ProMune, VaxImmune | |||||||
AH10-7 | 9899 | ||||||||
AH6809 | 1896 | AH 6809, AH-6809 | |||||||
AJ2-30 | 13090 | compound 4 [PMID: 38191941] | |||||||
AL-78898A | 9219 | 4(1MeW), POT-4 | |||||||
alcaftadine | 7587 | Lastacaft®, R-89674 | |||||||
alefacept | 6787 | Amevive®, BG 9273, BG 9712, BG-9273, BG-9712, Lfa3Tip | |||||||
alemtuzumab | 6770 | campath 1H, Campath®, campath-1H, Lemtrada® | |||||||
alimemazine | 7237 | Nedeltran®, trimeprazine | |||||||
3 alpha-aminocholestane | 9564 | 3AC, 3 α-aminocholestane | |||||||
ALT-803 | 9615 | IL-15 N72D:IL-15RαSu/Fc, IL-15SA, N-803 | |||||||
alvelestat | 6476 | AZD 9668, AZD-9668, AZD9668, KB-105160 | |||||||
AM-461 | 10170 | AM461, Compound 1 [WO2011085033] | |||||||
AM-6120 | 10119 | AM6120, peptide 41 [PMID: 30346167] | |||||||
amcinonide | 7060 | CL-34699, Cyclocort® | |||||||
amelenodor | 13384 | example 2 [WO2020010132A1], NX-13, NX13 | |||||||
amelubant | 8463 | BIIL 284, BIIL-284 | |||||||
AMG319 | 8917 | AMG 319, AMG-319 | |||||||
AMG487 | 13071 | AMG 487, AMG-487, compound 47 [PMID: 17448658] | |||||||
AMG820 | 9106 | ||||||||
aminopyridine 2 | 10051 | ||||||||
amiselimod | 9319 | Example 1 [US20090137530], MT-1303, MT1303 | |||||||
amiselimod phosphate | 9491 | amiselimod-P, MT-1303-P | |||||||
amlexanox | 7113 | AA-673, Amlexanox®, Aphthasol®, CHX-3673 | |||||||
amphiregulin | 4864 | colorectal cell-derived growth factor (CRDGF) | |||||||
AMT-101 | 11645 | ||||||||
AMY109 | 12789 | AMY-109, H1009/L395-F1974m | |||||||
anakinra | 6972 | antril, Kineret® | |||||||
anatumomab mafenatox | 9947 | 5T4FabV13SEAD227A, ABR 214936, ABR-214936, ABR214936, pMB125, PNU 214936, PNU-214936, PNU214936, TTS-CD2 | |||||||
ancriviroc | 804 | SCH 351125, SCH-351125, SCH-C | |||||||
andecaliximab | 9510 | GS-5745, GS5745 | |||||||
andrographolide | 9675 | ||||||||
anifrolumab | 8258 | anifrolumab-fnia, MDX-1333, MEDI-546, Saphnelo® | |||||||
apafant | 1860 | WEB 2086 BS, WEB-2086 | |||||||
apilimod | 9859 | LAM-002A (apilimod dimesylate), LAM002A, STA 5326, STA-5326, STA5326 | |||||||
apratastat | 6482 | compound 5h [PMID: 16426848], TMI-05, TMI005 | |||||||
apremilast | 7372 | CC-10004, Otezla® | |||||||
APRIL | 5068 | A proliferation-inducing ligand, TALL2, TNF- and APOL-related leukocyte expressed ligand 2, TNF-related death ligand 1, TRDL-1, ZTNF2 | |||||||
Apta-1 | 13556 | ||||||||
AR-9281 | 13112 | AR9281, compound 14a [PMID: 21211973] | |||||||
arformoterol | 7479 | (-)-Formoterol, (R,R)-Formoterol, Brovana®, YM-08316 | |||||||
ARN19702 | 10120 | ARN-19702, compound 8 [PMID: 27404798] | |||||||
ARN726 | 9178 | ARN-726, compound 6 [PMID: 25874594] | |||||||
(R)-ARN2508 | 9000 | compound (-)-10r [PMID: 26774927], example 19 [WO2014023643] | |||||||
(S)-ARN2508 | 8999 | compound (+)-10r [PMID: 26774927], example 20 [WO2014023643] | |||||||
arpromidine | 1221 | ARP | |||||||
ARRY-371797 | 11095 | ARRY-797, ARRY371797, ARRY797, compound 7 [PMID: 19950901] | |||||||
ARRY-382 | 9108 | ARRY 382, ARRY382, c-Fms-IN-12, PF-07265804, PF07265804 | |||||||
ARRY-502 | 10179 | ARRY502, example 237, enantiomer 1 [WO2009158426A1] | |||||||
AS101 | 437 | ammonium tri-chloro(dioxoethylene-O,O'-)tellurate, AS 101, AS-101 | |||||||
AS-252424 | 10578 | AS252424, compound 26 [PMID: 16789742] | |||||||
asapiprant | 11951 | BGE-175, BGE175, example II-74 [US8153793B2], S-555739 | |||||||
asimadoline | 9279 | EMD 61 753, EMD 61753, EMD-61753 | |||||||
asivatrep | 9621 | Example 230 [US7858621], PAC-14028 | |||||||
ASP4058 | 9569 | ASP-4058 | |||||||
aspirin | 4139 | Acetophen®, acetylsalicylic acid, Aspirin® | |||||||
aspirin-triggered resolvin D1 | 6239 | AT-Resolvin D1, AT-RvD1 | |||||||
AT38 | 9020 | [3-(aminocarbonyl)furoxan-4-yl]methyl salicylate | |||||||
atacicept | 9517 | TACI-Fc, TACI-Ig | |||||||
atezolizumab | 7990 | MPDL3280A, Tecentriq® | |||||||
ATI-50001 | 12317 | ATI-501, ATI50001, ATI501, example 103 [WO2007070872A1] | |||||||
atibuclimab | 11326 | IC14 | |||||||
atracurium | 9537 | atracurium besilate, atracurium dibesylate, BW 33A, Tracrium® | |||||||
auranofin | 6306 | Ridaura®, SK&F-39162, SK-39162 | |||||||
avacincaptad pegol | 12857 | ARC-1905, ARC1905, Izervay®, Zimura | |||||||
avacopan | 9450 | CCX-168, CCX168, Tavneos® | |||||||
avadomide | 10522 | CC-122, CC122, Compound A [WO2014039960A1] | |||||||
avapritinib | 10368 | Ayvakit®, Ayvakyt®, BLU-285, BLU285 | |||||||
avdoralimab | 11345 | anti-hC5aR-32F3A6 GL, IPH-5401, NN-8210, NNC-0215-0384 | |||||||
AVE 0991 | 5579 | AVE-0991, AVE0991 | |||||||
avelumab | 8735 | Bavencio®, MSB-0010718C, MSB0010718C | |||||||
AX-024 | 11253 | AX-24, AX024 | |||||||
AZ13102909 | 9577 | AZ909 | |||||||
AZ2 | 10233 | ||||||||
AZ3451 | 9560 | ||||||||
AZ7188 | 9586 | ||||||||
AZ8838 | 9585 | ||||||||
azacitidine | 6796 | 5-AZAC, 5-azacytidine, ladakamycin, Onureg®, Onureg® (CC-486; oral azacitidine), U-18496, Vidaza® | |||||||
azapro-3 | 9221 | ||||||||
azatadine | 7119 | Optimine®, SCH-10649 | |||||||
azathioprine | 7120 | Azasan®, BW-57-322, Imuran®, Jayempi® | |||||||
AZD0284 | 11711 | AZD-0284, compound 20 [PMID: 34464130] | |||||||
AZD1236 | 7844 | AZD 1236, AZD-1236 | |||||||
AZD1678 | 9679 | AZD-1678, compound 49 [PMID: 28947948] | |||||||
AZD1981 | 7680 | AZD 1981, AZD-1981 | |||||||
AZD2098 | 9678 | AZD-2098, compound 47 [PMID: 28947948] | |||||||
AZD2423 | 7825 | AZD 2423, AZD-2423 | |||||||
AZD3458 | 9997 | AZD-3458, compound 15 [PMID: 29852070] | |||||||
AZD3965 | 10605 | AZD-3965 | |||||||
AZD5069 | 8948 | AZD-5069 | |||||||
AZD5423 | 13017 | AZD-5423, compound 1b [PMID: 28937774] | |||||||
AZD5672 | 7686 | AZD 5672, AZD-5672 | |||||||
AZD5718 | 10352 | compound 12 [PMID: 30869888] | |||||||
AZD6605 | 7823 | AZ 11920155, AZ-11920155, AZ11920155, AZD 6605, AZD-6605 | |||||||
AZD6703 | 7687 | AZ 12012199, AZ-12012199, AZ12012199, AZD 6703, AZD-6703 | |||||||
AZD7624 | 11714 | AZD-7624, Example 259 [WO2009001132] | |||||||
AZD8154 | 11204 | AZD-8154, Example 1 [WO2018055040A1] | |||||||
AZD8848 | 9256 | DSP-3025 | |||||||
AZD9056 | 7826 | AZD 9056, AZD-9056 | |||||||
AZD9567 | 9812 | AZD 9567, AZD-9567, compound 15 [PMID: 29424542], example 1 [WO2016046260A1] | |||||||
AZD9898 | 10479 | AZD-9898, example 62 [WO2016177845A1] | |||||||
azelaic acid | 7484 | Azelex®, Finacea®, ZK-62498 | |||||||
azithromycin | 6510 | ||||||||
AZ11657312 (salt free) | 7722 | ||||||||
B | Back to top | ||||||||
bafetinib | 7906 | INNO-406, Lyn-IN-1, NS-187 | |||||||
BAFF | 5069 | B cell-activating factor, CD257 antigen, dendritic cell-derived TNF-like molecule | |||||||
baicalin | 13076 | 7-D-glucuronic acid-5,6-dihydroxy-flavone, Baicalein 7-glucuronide, compound 15 [PMID: 37666112] | |||||||
balamapimod | 9925 | MKI-833, MKI833 | |||||||
B and T lymphocyte attenuator | 4891 | BTLA, B- and T-lymphocyte attenuator , B- and T-lymphocyte-associated protein, CD272 | |||||||
bardoxolone | 2717 | CDDO, RTA-401 | |||||||
baricitinib | 7792 | INCB-028050, INCB028050, LY-3009104, LY3009104, Olumiant® | |||||||
basiliximab | 6879 | CHI-621, L04AC02, SDZ-CHI-621, Simulect® | |||||||
BAY 11-7082 | 5934 | (E)-3-tosylacrylonitrile, BAY-117082, BAY117082 | |||||||
BAY1830839 | 13101 | BAY-1830839, example 11 [WO2016083433A1] | |||||||
BAY-985 | 10597 | BAY985, compound 34 [PMID: 31859507] | |||||||
BAYu9773 | 3381 | BAY u9773, BAY-u 9773 | |||||||
BC-1215 | 12671 | BC 1215, BC1215 | |||||||
beclometasone | 7059 | beclomethasone, SCH-18020W | |||||||
beclometasone dipropionate | 5894 | beclomethasone dipropionate, Beconase®, Qnasl®, Vancenase® | |||||||
begelomab | 8691 | Begendina&rg; (proprietary name), BT 5/9, SAND 26 | |||||||
belantamab mafodotin | 11117 | belamaf, belantamab mafodotin-blmf, Blenrep®, GSK-2857916, GSK2857916 | |||||||
belatacept | 6892 | BMS-224818, LEA29Y, Nulojix® | |||||||
belimumab | 6887 | Benlysta®, hBlySmAb-1.1, LimphoStat-B, lymphostat-B | |||||||
belnacasan | 9035 | HMR3480, VX-765 | |||||||
belumosudil | 9558 | KD-025, KD025, Rezurock®, SLx 2119, SLx2119 | |||||||
bempegaldesleukin | 10659 | NKTR-214, NKTR214 | |||||||
benralizumab | 7674 | BIW-8405, Fasenra®, KHK4563, MEDI-563 | |||||||
bentamapimod | 9926 | AS-602801, AS602801, PGL-5001, PGL5001 | |||||||
benzodrocortisone | 9731 | compound 1 [WO2013071010], hydrocortisone 17-benzoate | |||||||
3beta-Hydroxy-20(29)-lupene | 9028 | Fagarasterol, Lupeol | |||||||
betamethasone | 7061 | SCH-4831 | |||||||
bexmarilimab | 12907 | Clevegen, FP-1305, FP1305 | |||||||
BI-1935 | 9717 | BI 1935, example 3 [WO2007067836] | |||||||
BI-1950 | 9719 | ||||||||
BI-2545 | 9791 | BI2545, compound 19 [PMID: 29259743] | |||||||
BI605906 | 9357 | 3-Amino-4-(1,1-difluoro- propyl)-6-(4-methanesulfonyl- piperidin-1-yl)-thieno[2,3- b]pyridine-2-carboxylic acid amide, compound 115 [US20070293533] | |||||||
BI 653048 | 9715 | (R)-39, BI 653048 BS H3PO4, BI-653048, BI653048 | |||||||
BI 665915 | 9716 | BI-665915, compound 69 [PMID: 25671290] | |||||||
BI-6901 | 9714 | BI 6901, BI 6901, BI6901, eut-22 | |||||||
bifikafusp alfa | 9756 | Darleukin, L19-IL2, L19IL2 | |||||||
bihelical apoA-I mimetic peptide 5A | 9183 | 5A peptide | |||||||
BIIB068 | 11178 | BIIB-068, compound 1 [PMID: 32696648] | |||||||
bimekizumab | 9411 | bimekizumab-bkzx, Bimzelx®, CA028_0496, CDP4940, gL7gH9, UCB-4940, UCB4940, Zu-G1 | |||||||
bimosiamose | 9049 | compound 15e [PMID: 9544210], TBC 1269, TBC-1269, TBC1269 | |||||||
bindarit | 11124 | AF-2838, AF2838 | |||||||
BIO-7488 | 13341 | BIO7488 | |||||||
BIO-8169 | 13355 | BIO8169, compound 2 [PMID: 38695469] | |||||||
BIRT 377 | 9720 | BIRT-377 | |||||||
blinatumomab | 7384 | Blincyto®, bscCD19xCD3, MEDI-538, MT-103, MT103 | |||||||
blisibimod | 9518 | A-623, AGP3 peptibody, AMG 623, Fc-Agp-3 | |||||||
BML-281 | 9664 | compound 3 [PMID: 18642892] | |||||||
BMS-1001 | 10191 | BMS1001, Example 1001 [WO2015160641A2] | |||||||
BMS-1166 | 9608 | compound 2c [PMID: 28613862], Example 1166 [WO2015160641A2] | |||||||
BMS-202 | 9607 | compound 1c [PMID: 28613862], PD1-PDL1 inhibitor 2 | |||||||
BMS-345541 | 5669 | BMS 345541, BMS345541 | |||||||
BMS-509744 | 9994 | BMS 509744, BMS509744, compound 3 [PMID:16682193] | |||||||
BMS-561392 | 6509 | BMS 561392, BMS561392, DPC-333 | |||||||
BMS-582949 | 7838 | BMS 582949, BMS582949, PS 540446, PS-540446, PS540446 | |||||||
BMS-681 | 9430 | compound 13d [PMID: 25893046] | |||||||
BMS-817399 | 9497 | compound 29 [PMID: 25101488] | |||||||
BMS-986142 | 9857 | BMS986142, compound 14f [PMID: 27583770] | |||||||
BMS-986166 | 11493 | BMS986166, compound 14a [PMID: 30785748] | |||||||
BMS-986235 | 11024 | BMS986235, compound 13c [PMID: 32407089], LAR-1219, LAR1219 | |||||||
BMS-986260 | 10662 | BMS986260, compound 10 [Velaparthi et al., 2020], Example 32' [WO2016140884A1] | |||||||
BMS-986104 derivative 12 | 11494 | compound 12 [PMID: 33492963] | |||||||
BMS-986104 derivative 24 | 11495 | compound 24 [PMID: 33492963] | |||||||
bortezomib | 6391 | peptide boronate, PS-341, Velcade® | |||||||
bosutinib | 5710 | Bosulif®, SK 606, SK-606, SKI 606 | |||||||
branebrutinib | 9869 | BMS-986195, BMS986195, Example 223 [US20160115126A1] | |||||||
brazikumab | 9293 | AMG 139, AMG-139, MEDI2070 | |||||||
brensocatib | 9412 | AZD7986, compound 30, INS 1007, INS1007 | |||||||
brentuximab vedotin | 6772 | Adcetris®, anti-CD30 ADC SGN-35, SGN 35 | |||||||
brepocitinib | 10459 | compound 23 [PMID: 30113844], PF-06700841, PF06700841 | |||||||
briakinumab | 9213 | ABT-874, J-695, J695, Ozespa | |||||||
brimapitide | 9101 | AM-111, D-JNKI-1, XG-102 | |||||||
brimonidine (UK14304) | 520 | Alphagan®, Lumify®, Mirvaso®, UK14,304, UK14304 | |||||||
briquilimab | 13450 | AMG-191, AMG191, JSP-191, JSP191 | |||||||
BRL-15572 | 10 | BRL 15572, BRL-15,572, BRL15572 | |||||||
brodalumab | 7540 | AMG-827, AMG827, Kyntheum®, Lumicef®, Siliq® | |||||||
bromfenac | 7131 | AHR-10282B, Bromday®, Prolensa®, Xibrom® | |||||||
BsAb (CD89-CD20) | 9833 | ||||||||
BT7480 | 12060 | BCY11863, BT-7480 | |||||||
BTP2 | 2438 | YM-58483 | |||||||
budesonide | 7434 | Entocort®, Eohilia® (budesonide oral suspension), Jorveza®, Pulmicort®, S-1320, Uceris® | |||||||
butyric acid | 1059 | butanoic acid, butyrate, C4 | |||||||
BX 471 | 767 | BX-471, BX-741 | |||||||
BX-795 | 8006 | BX 795, BX795 | |||||||
C | Back to top | ||||||||
C108297 | 9180 | Compound 52 [PMID:18226897] | |||||||
C1-27 | 10719 | GSTO1-IN-1 | |||||||
C-176 | 13136 | C-176 STING inhibitor | |||||||
C391 | 9570 | compound 5 [PMID: 27994760] | |||||||
C646 | 7004 | ||||||||
C5a | 573 | C5a anaphylatoxin, complement component C5a, human complement protein | |||||||
cabiralizumab | 9107 | BMS-986227, FPA-008, FPA008 | |||||||
cadonilimab | 12966 | AK-104, AK104 | |||||||
cambritaxestat | 13506 | compound 9v [PMID: 27780639], CRT-0273750, CRT0273750, IOA-289 | |||||||
camoteskimab | 13187 | AEVI 007, AEVI-007, AVTX 007, AVTX-007, CERC 007, CERC-007, MEDI 2338 | |||||||
camrelizumab | 9758 | INCSHR1210, SHR-1210 | |||||||
canakinumab | 6773 | ACZ 885, ACZ885, Ilaris® | |||||||
canertinib | 5675 | CI 1033, CI-1033, PD 183805 dihydrochloride | |||||||
carotegrast | 10511 | HCA2969 | |||||||
carotegrast methyl | 10510 | AJM-300, AJM300, Carogra® | |||||||
carprofen | 7141 | Ro-205720000 | |||||||
CBS-3595 | 9610 | ||||||||
CC-885 | 9224 | ||||||||
CCL1 | 4404 | ||||||||
CCL1 | 812 | I309, TCA-3 | |||||||
CCL11 | 4416 | ||||||||
CCL11 | 769 | eotaxin | |||||||
CCL11 | 787 | murine eotaxin | |||||||
CCL12 | 4435 | ||||||||
CCL13 | 770 | monocyte chemotactic protein-4 | |||||||
CCL14 | 753 | CCL14a, CKβ1, haemofiltrate CC chemokine 1 (HCC-1), HCC-1(1-74) | |||||||
CCL15 | 754 | Lkn-1 [Leukotactin-1], macrophage inflammatory protein-1δ, MIP-1δ | |||||||
CCL16 | 1272 | ||||||||
CCL17 | 797 | TARC, thymus- and activation-regulated chemokine | |||||||
CCL18 | 4382 | macrophage inflammatory protein 4, small-inducible cytokine A18 | |||||||
CCL19 | 810 | β-chemokine exodus-3, ck β-11, ckβ11, MIP-3β | |||||||
CCL19 | 4417 | ||||||||
CCL2 | 771 | ||||||||
CCL2 | 4407 | ||||||||
CCL2 | 4406 | ||||||||
CCL20 | 4419 | ||||||||
CCL20 | 808 | LARC, liver and activation-regulated chemokine, macrophage inflammatory protein-3α, MIP-3α | |||||||
CCL20 | 4418 | ||||||||
CCL21 | 811 | ckβ9, TCA-4 | |||||||
CCL22 | 4420 | ||||||||
CCL22 | 798 | dc/β-ck, macrophage-derived chemokine, STCP1 | |||||||
CCL23 | 755 | ckβ8-1, myeloid progenitor inhibitor factor-1 | |||||||
CCL24 | 4421 | ||||||||
CCL24 | 775 | eotaxin-2 | |||||||
CCL25 | 817 | ||||||||
CCL25 | 4422 | ||||||||
CCL26 | 776 | MIP-4α, PTEC | |||||||
CCL27 | 3646 | ||||||||
CCL27 | 4462 | ||||||||
CCL28 | 4463 | ||||||||
CCL28 | 3649 | ||||||||
CCL3 | 4408 | ||||||||
CCL3 | 756 | macrophage inflammatory protein-1α, MIP-1α | |||||||
CCL3 | 4409 | ||||||||
CCL4 | 4410 | ||||||||
CCL4 | 757 | HC21, macrophage inflammatory protein-1β, MIP-1β | |||||||
CCL4 | 4411 | ||||||||
CCL5 | 4412 | ||||||||
CCL5 | 758 | eosinophil chemotactic cytokine [EoCP], regulated upon activation normal T cell expressed and secreted (RANTES) | |||||||
CCL7 | 4414 | ||||||||
CCL7 | 759 | ||||||||
CCL7 | 4413 | ||||||||
CCL8 | 4415 | ||||||||
CCL8 | 772 | monocyte chemotactic protein-2 | |||||||
CCL9 | 4434 | ||||||||
Ccl21a | 8651 | 6Ckine-Ser, Exodus-2 | |||||||
Ccl21b | 8652 | 6Ckine-Leu, Exodus-2 | |||||||
CCR2-RA-[R] | 9431 | analog 49 (Dasse et al., 2007) | |||||||
CCX354 | 10164 | CCX 354, CCX-354, CCX-354-C | |||||||
CD40 ligand | 5077 | CD40 ligand, membrane form | |||||||
CDP840 | 9330 | CDP 840, CDP-840 | |||||||
CEE321 | 12350 | CEE-321, compound 1e [PMID: 36657024] | |||||||
celastrol | 10386 | compound 2 [PMID: 28621943] | |||||||
celecoxib | 2892 | Celecox®, Elyxyb® (DFN-15; oral solution), Onsenal®, SC-58635, SC58635 | |||||||
cemiplimab | 10090 | cemiplimab-rwlc, Libtayo®, REGN-2810, REGN2810, SAR-439684, SAR439684 | |||||||
cenerimod | 9824 | ACT-334441 | |||||||
cenicriviroc | 801 | TAK 652, TAK-652, TAK652, TBR-652 | |||||||
cerdulatinib | 8957 | PRT 062070, PRT-062070, PRT-2070, PRT062070 | |||||||
certolizumab pegol | 6774 | CDP870, Cimzia®, PHA 738144 | |||||||
cetirizine | 1222 | Reactine®, Zyrtec® | |||||||
cetrorelix | 1190 | Cetrotide®, SB-075 | |||||||
CFZ533 | 9802 | CFZ-533, iscalimab (proposed INN), NVP-CFZ533, OM11-62MF | |||||||
CG200745 | 10055 | CG-2, CG-200745, HDCG-0745 | |||||||
2'3'-cGAMP | 9207 | cyclic [G(2',5')pA(3',5')p], cyclic GMP-AMP, Cyclic guanosine monophosphate-adenosine monophosphate | |||||||
CGI1746 | 8066 | CGI 1746, CGI-1746 | |||||||
CGI560 | 9264 | CGI-560 | |||||||
CH-4051 | 9844 | Formula (10) [WO2012078708A1] | |||||||
chloroquine | 5535 | Aralen®, chloraquine, Malaquin® | |||||||
CHMFL-BTK-11 | 9516 | ||||||||
cibinetide | 9677 | ARA 290, ARA-290, PH-BSP, PHBSP | |||||||
cicaprost | 1917 | ZK 96480, ZK-96480 | |||||||
ciclesonide | 7469 | Alvesco®, Omnaris®, RPR-251526 | |||||||
ciforadenant | 10190 | CPI-444, CPI444, V-81444, V81444 | |||||||
cilomilast | 7407 | SB-207499 | |||||||
cintirorgon | 10045 | compound 32J [WO2016201225A1], LYC-55716, LYC55716 | |||||||
cipemastat | 6466 | Ro 28-2653 | |||||||
civorebrutinib | 12868 | ||||||||
clazakizumab | 9195 | ALD-518, ALD518, BMS-945429 | |||||||
clemastine | 6063 | HS-592, meclastin, Tavegil®, Tavist® | |||||||
clemizole | 10285 | ||||||||
clobenpropit | 1223 | VUF 9153, VUF-9153 | |||||||
clobetasol propionate | 7062 | CCI-4725, Clobex®, Dermovate®, GR 2/925, Temovate® | |||||||
clobetasone | 9088 | Eumovate® | |||||||
clodronic acid | 9605 | Bonefos®, Clasteon ®, clodronate, Loron® | |||||||
clofazimine | 9184 | Lamprene® | |||||||
clopidogrel (active metabolite) | 1772 | ||||||||
CM4620 | 10087 | CM-4620, compound I [WO2016138472A1] | |||||||
CNX-774 | 9266 | ||||||||
colchicine | 2367 | Colcrys®, methoxylated analogue of XD1, XD25 | |||||||
complement C3 | 9414 | ||||||||
complement C5 | 8712 | ||||||||
compound 48/80 | 5531 | ||||||||
compound 3a [Pipionne et al, 2018] | 9965 | ||||||||
compound 10a [PMID: 31283223] | 10435 | ||||||||
compound 12a [PMID: 29031075] | 9684 | ||||||||
compound 19a [PMID: 26506089] | 9842 | ||||||||
compound 8a [PMID: 23713581] | 8856 | ||||||||
compound 21b [PMID: 31136173] | 10403 | ||||||||
compound 5b [PMID: 29457898] | 9835 | ||||||||
compound 5b [PMID: 31287314] | 10434 | ||||||||
compound 18c [PMID: 25901531] | 9227 | ||||||||
compound 3c [PMID: 30360354] | 10591 | [As(4-F)F4]-GHRP-6, azasulfuryl-p-fluorophenylalanine-4-[As(4-F)F4]-GHRP-6, H-His-D-Trp-Ala-(4-F)AsF-D-Phe-Lys-NH2 | |||||||
compound 7c [PMID: 22041175] | 9931 | ||||||||
compound 8c [PMID: 28760529] | 9671 | ||||||||
Compound 9 [doi:10.26434/chemrxiv.7072592.v1] | 10083 | ||||||||
compound 17d [PMID: 23099093] | 8196 | ||||||||
compound 5d [PMID: 31335136] | 10441 | Example 59 [WO2018121550] | |||||||
compound 7d [PMID: 29672049] | 9937 | ||||||||
compound 18e [PMID: 31670517] | 10549 | ||||||||
compound 4e [PMID: 35546685] | 12122 | CHF-6297, CHF6297, CHI 91040, CHI91040, p38α MAPK-IN-5 | |||||||
compound 5e [PMID: 28580438] | 9712 | ||||||||
compound 14f [PMID: 35063894] | 11936 | ||||||||
compound 20f [PMID: 28520415] | 9961 | ||||||||
compound 7f [PMID: 29191554] | 9794 | example 32 [WO2011078413] | |||||||
compound 7f [PMID: 29283260] | 9780 | ||||||||
compound 2g [PMID: 27390066] | 9682 | ||||||||
compound 4g [PMID: 2680437] | 9198 | ||||||||
compound G1 [PMID: 36689364] | 12354 | ||||||||
compound 8ic [PMID: 19081254] | 9478 | CCR4 Antagonist | |||||||
compound III [PMID: 24045148] | 9709 | ||||||||
compound II [PMID: 21329883] | 9579 | ||||||||
compound 16i [PMID: 31525963] | 10502 | ||||||||
compound 5i [PMID: 36542759] | 12336 | ||||||||
compound 9 [Kumar et al., 2019] | 10448 | ||||||||
compound 17l [PMID: 26288691] | 10035 | ||||||||
compound 29 [Moslin et al., 2017] | 9992 | ||||||||
compound 12p [Larson et al., 2017] | 9690 | ||||||||
compound 10 [PMID: 31411465] | 10488 | example 8 (cis racemate) [WO2017060855A1] | |||||||
compound 11 [PMID: 29442501] | 9819 | ||||||||
compound 12 [PMID: 27448772] | 9453 | ||||||||
compound 15 [PMID: 25411721] | 9078 | example 252 [WO2007110237] | |||||||
compound 15 [PMID: 32045236] | 10706 | ||||||||
compound 16 [PMID: 26794040] | 9223 | ||||||||
compound 16 [PMID: 31525966] | 10501 | ||||||||
compound 17 [PMID: 29741897] | 10005 | ||||||||
compound 182 [PMID: 37500611] | 13005 | compound XI [PMID: 37500611] | |||||||
compound 1 [PMID: 24930776] | 9092 | DB36 | |||||||
compound 1 [PMID: 28611375] | 9673 | ||||||||
compound 1 [PMID: 31477924] | 10481 | ||||||||
compound 21 [PMID: 22802221] | 6918 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt, C21 | |||||||
compound 21 [PMID: 24900635] | 8187 | ||||||||
compound 24 [PMID: 26987013 ] | 9252 | ||||||||
compound 25 [PMID: 28038940] | 9700 | ||||||||
compound 25 [PMID: 31260299] | 10428 | ||||||||
compound 25 [PMID: 32105470] | 10718 | ||||||||
compound 25 [PMID: 32687365] | 11130 | ||||||||
compound 26 [PMID: 31710475] | 10602 | ||||||||
compound 27 [PMID: 24900635] | 10133 | ||||||||
compound 28 [PMID: 28671460] | 9670 | ||||||||
compound 29 [PMID: 31934767] | 10596 | ||||||||
compound 2 [PMID: 28621538] | 11282 | example 727 [WO2012093101A1] | |||||||
compound 31 [PMID: 31259550] | 10417 | ||||||||
compound 32 [PMID: 31638797] | 10528 | example 69 [WO2016179460A1] | |||||||
compound 32 [PMID: 38047891] | 13050 | ||||||||
compound 36 [PMID: 21958547] | 9391 | ||||||||
compound 37 [PMID: 29193967] | 9797 | ||||||||
compound 39 [PMID: 31742400] | 10585 | ||||||||
compound 3 [PMID: 28603634] | 9628 | ||||||||
compound 3 [PMID: 29633584] | 9960 | ||||||||
compound 41 [PMID: 25000588] | 9349 | ||||||||
compound 41 [PMID: 31855425] | 10598 | ||||||||
compound 43 [PMID: 26751273] | 9492 | ||||||||
compound 47 [PMID: 28737909] | 9646 | ||||||||
compound 49 [PMID: 36529947] | 12355 | ||||||||
compound 52 [PMID: 28541707] | 10001 | ||||||||
compound 76 [PMID: 28657314] | 9609 | ||||||||
compound 7 [PMID: 31381331] | 10450 | ||||||||
compound 8 [PMID: 25898023] | 10498 | ||||||||
compound 9 [PMID: 26006010] | 9761 | ||||||||
compound (S)-29 [PMID: 37606563] | 12904 | ||||||||
compound 2q [PMID: 30986068] | 10365 | example 2-8 [US20150353552] | |||||||
compound 14 [Schnute et al., 2023] | 12351 | ||||||||
compound T.14 | 10385 | ||||||||
compound 8u [PMID: 31999451] | 10682 | ||||||||
compound 3v [PMID: 27390066] | 9683 | ||||||||
compound 1 [WO2012007375] | 8084 | ||||||||
compound 7 [WO2012007375] | 8085 | ||||||||
compound 71 [WO2018191577A1] | 11203 | ||||||||
compound XVI [PMID: 38863440] | 13423 | ||||||||
compound 25 [Zhang et al., 2020] | 10643 | example 6B [WO2014028600A2] | |||||||
compound 15z [PMID: 38029358] | 13044 | NLRP3 inhibitor 15z | |||||||
compstatin | 9218 | ||||||||
CORM-2 | 9535 | ||||||||
corticosterone | 2869 | ||||||||
corticotropin zinc hydroxide | 6967 | ||||||||
cortisol | 2868 | Acticort®, Efmody®, Plenadren® | |||||||
COVA322 | 10469 | ||||||||
CP105696 | 3368 | CP 105696, CP-105,696, CP-105696 | |||||||
CP-195543 | 6155 | CP 195543, CP-195,543, CP195543 | |||||||
CP-412,245 | 11809 | ||||||||
CP-424,174 | 11810 | CP-424174 | |||||||
CpdA (parent molecule) | 11317 | ||||||||
CPUY192018 | 9710 | compound 18e [PMID: 26258437], compound 2 [PMID: 24512214] | |||||||
CR6086 | 9845 | ||||||||
CRAC channel inhibitor 5b [PMID: 26256403] | 10042 | ||||||||
CRAC channel inhibitor 1 [PMID: 26256403] | 10041 | ||||||||
CRAMP | 6266 | ||||||||
crenolanib | 7882 | ARO-002, CP 868596, CP-868,596, CP-868596 | |||||||
crisaborole | 9151 | AN 2728, AN2728, compound 5b [PMID: 19303290], Eucrisa®, Staquis® | |||||||
crizotinib | 4903 | (R)-crizotinib, PF 2341066, PF-02341066, PF-2341066, PF2341066, Xalkori® | |||||||
cromoglicic acid | 7608 | cromoglycate, cromolyn, cromolyn sodium, FPL-670, Intal®, Opticrom®, sodium cromoglicate | |||||||
crovalimab | 12790 | crovalimab-akkz, Piasky®, RG-6107, RG6107, Senkai® (China), SKY59 | |||||||
CRX-555 | 10091 | CRX555, N-[(3R)-3-(Octanoyloxy)myristoyl]-O-[2-[[(3R)-3-(octanoyloxy)myristoyl]amino]-3-O-[(3R)-3-(octanoyloxy)myristoyl]-4-O-phosphono-2-deoxy-beta-D-glucopyranosyl]-L-serine | |||||||
CU-CPT8m | 9795 | 7-(m-Tolyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, compound 5 [PMID: 29155428] | |||||||
cusatuzumab | 9778 | ARGX-110, ARGX110, clone 41D12 | |||||||
CVN293 | 13373 | CVN-293 | |||||||
CX549 | 9701 | compound 63 [WO2016048861], CX-549 | |||||||
CXCL1 | 4423 | ||||||||
CXCL1 | 826 | CINC, GROα, macrophage inflammatory protein-2 | |||||||
CXCL1 | 819 | GROα, melanocyte growth-stimulatory activity, MIP-2 | |||||||
CXCL10 | 835 | ||||||||
CXCL10 | 4430 | ||||||||
CXCL10 | 4431 | ||||||||
CXCL11 | 4432 | ||||||||
CXCL11 | 836 | IP9, ITAC | |||||||
CXCL12 | 4465 | ||||||||
CXCL12α | 4358 | CXCL12 α, SDF-1α, stromal cell-derived factor-1α | |||||||
CXCL12β | 845 | SDF-1β, stromal cell-derived factor-1 (SDF-1), stromal cell-derived factor-1β | |||||||
CXCL12δ | 8531 | ||||||||
CXCL12ε | 8532 | ||||||||
CXCL12γ | 8530 | ||||||||
CXCL12φ | 8533 | ||||||||
CXCL13 | 3645 | BCA-1 | |||||||
CXCL13 | 4466 | ||||||||
CXCL14 | 3680 | BMAC | |||||||
CXCL15 | 3862 | lungkine (mouse) | |||||||
CXCL16 | 4433 | ||||||||
CXCL16 | 4467 | ||||||||
CXCL16 | 855 | ||||||||
CXCL17 | 6479 | C-X-C motif chemokine 17, dendritic cell and monocyte chemokine-like protein | |||||||
CXCL2 | 4424 | macrophage inflammatory protein 2 (MIP-2) | |||||||
CXCL2 | 4425 | ||||||||
CXCL2 | 827 | GROβ, MIP-2α | |||||||
CXCL3 | 4427 | ||||||||
CXCL3 | 4426 | ||||||||
CXCL3 | 828 | GROγ, MIP-2β | |||||||
CXCL4 | 3685 | platelet factor 4 (PF4) | |||||||
CXCL5 | 829 | ENA-78 | |||||||
CXCL5 | 4464 | ||||||||
CXCL5 | 4428 | ||||||||
CXCL6 | 820 | ||||||||
CXCL7 | 830 | PPBP | |||||||
CXCL8 | 821 | interleukin-8 | |||||||
CXCL9 | 4429 | ||||||||
CXCL9 | 837 | MIG, monokine induced by gamma-interferon | |||||||
CX3CL1 | 4469 | ||||||||
CX3CL1 | 4468 | ||||||||
CX3CL1 | 856 | fractalkine, neurotactin | |||||||
CXCR4 antagonist 22 | 10146 | ||||||||
CY-09 | 10057 | ||||||||
cyclic di-GMP | 13137 | Bis-(3'-5')-cyclic dimeric guanosine monophosphate, c-di-GMP, cGpGp, dyclic diguanylate monophosphate | |||||||
cyclosporin A | 1024 | ciclosporin, cyclosporine, cyclosporine A, Ikervis® (opthalmic solution), Neoral®, Sandimmun®, Verkazia® (opthalmic solution) | |||||||
CZ415 | 9837 | compound 3 [PMID: 27563401], CZ-415 | |||||||
D | Back to top | ||||||||
D4476 | 5940 | casein kinase I inhibitor, CK1 inhibitor, D 4476 | |||||||
daclizumab | 6880 | L04AC01, RO-24-7375, Ro-247375, Zenapax® | |||||||
dagrocorat | 9650 | PF-00251802 | |||||||
danirixin | 8500 | GSK-1325756B, GSK1325756, GSK1325756B | |||||||
dapansutrile | 10056 | OLT-1177, OLT1177 | |||||||
dapirolizumab pegol | 11123 | CDP-7657, CDP7657, DZP | |||||||
darapladib | 6696 | SB 480848, SB-480848 | |||||||
daratumumab | 7395 | 3003-005, Darzalex®, HuMax-CD38, JNJ-54767414 | |||||||
dasatinib | 5678 | BMS 345825, BMS 354825, BMS 35482513, Sprycel® | |||||||
dazodalibep | 13453 | MEDI-4920, MEDI4920, VIB 4920, VIB-4920, VIB4920 | |||||||
DDR1/2 inhibitor 5n | 10105 | ||||||||
decernotinib | 8309 | adelatinib, VRT-831509, VX-509 | |||||||
dectrekumab | 8714 | QAX-576, QAX576 | |||||||
deflazacort | 9477 | Emflaza®, MDL 458 | |||||||
defoslimod | 9024 | OM 174, OM-174 | |||||||
delgocitinib | 9619 | Corectim®, ent-60, JTE-052, JTE052 | |||||||
denileukin diftitox | 7044 | DAB389 IL2, denileukin diftitox-cxdl, LY 335348, Lymphir®, Ontak® | |||||||
14-Deoxy-11,12-didehydroandrographolide | 13464 | ddA (14-deoxy-11,12-didehydroandrographolide) | |||||||
desloratadine | 7157 | Clarinex®, SCH-34117 | |||||||
desonide | 7066 | D-2083, Desowen® | |||||||
desoximetasone | 7067 | A-41-304, HOE-304, R-2113, Topicort® | |||||||
deucravacitinib | 10432 | BMS-986165, BMS986165, compound 11 [PMID: 31318208}, Sotyktu®, Tyk2-IN-4 | |||||||
deuruxolitinib | 11410 | CTP-543, CTP543, D8-ruxolitinib, Leqselvi® | |||||||
dexamethasone | 2768 | Decadron®, desametasone, fluormethylprednisolone | |||||||
dezapelisib | 9728 | compound 67 [PMID: 22924688], example 15 [WO2011008487], INCB 40093, INCB40093 | |||||||
DFV890 | 13525 | DFV-890, IFM-2427, IFM2427 | |||||||
diamorphine | 9082 | acetomorphine, diacetylmorphine, heroin | |||||||
diclofenac | 2714 | Cataflam®, CGP-45840B, GP-45840, Voltaren®, Voltarol® | |||||||
difamilast | 9776 | example 352 [WO2007058338], MM36, Moizerto®, OPA-15406 | |||||||
difelikefalin | 9044 | CR845, D-Phe-D-Phe-D-Leu-D-Lys-[γ-(4-N-piperidinyl)amino carboxylic acid], FE-202845, Kapruvia®, Korsuva®, SEQ ID NO: 2 | |||||||
diflapolin | 10080 | ||||||||
diflorasone diacetate | 7068 | Psorcon®, U-34865 | |||||||
diflunisal | 7162 | Dolobid® | |||||||
difluprednate | 7474 | DFBA, Durezol®, W-6309 | |||||||
dilmapimod | 7815 | SB-681323 | |||||||
dimethyl fumarate | 7045 | BG-12, BG00012, fumaric acid, Tecfidera® | |||||||
dimethyl itaconate | 9939 | dimethylitaconate, itaconic acid dimethyl ester | |||||||
dimetindene | 10101 | (+/-)-dimethindene, dimethindene, dimethpyrindene, Fenistil®, Vibrocil® | |||||||
(S)-dimetindene | 10104 | (+)-dimethindene, (+)-dimetindene, (S)-dimethindene | |||||||
diminazene | 10307 | Azidin®, Berenil®, Pirocide® | |||||||
dinaciclib | 7379 | SCH727965 | |||||||
diphenylpyraline | 7165 | Hispril® | |||||||
diprovocim-1 | 10341 | compound 3 [PMID: 30272974] | |||||||
diroleuton | 9775 | 8,11,14-Eicosatrienoic acid, DGLA, dihomo-gamma-linolenic acid, DS107, Homo-gamma-linolenic acid | |||||||
diroximel fumarate | 10525 | ALKS-8700, ALKS8700, BIIB098, Vumerity® | |||||||
divozilimab | 13087 | BCD 132, BCD-132, Ivlizi® | |||||||
DMAT | 9323 | 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole, CK2 Inhibitor II | |||||||
DO264 | 10250 | compound 46, DO-264 | |||||||
dopamine | 940 | 3-hydroxytyramine | |||||||
doramapimod | 5668 | BIRB 796BS, BIRB-796, BIRB796 | |||||||
dostarlimab | 11518 | ANB-011, dostarlimab-gxly, Jemperli®, TSR-042, WBP-285 | |||||||
doxycycline | 6464 | BMY-28689, Monodox®, Vibramycin® | |||||||
dual sEH/FAAH inhibitor 11 | 10124 | compound B-11 [WO2017160861], example 28 [WO2017160861] | |||||||
dubermatinib | 8863 | compound 13, TP 0903, TP-0903, TP0903 | |||||||
dupilumab | 7574 | Dupixent®, REGN668, SAR231893 | |||||||
durvalumab | 7985 | anti-B7H1 monoclonal antibody, Imfinzi®, MEDI-4736, MEDI4736 | |||||||
duvelisib | 7795 | compound 4904 [Patent US8193182], Copiktra®, INK-1197, IPI-145 | |||||||
DX-2507 | 9959 | ||||||||
dyphylline | 7070 | Dilor® | |||||||
E | Back to top | ||||||||
6E11 | 9749 | ||||||||
E-52862 | 10431 | compound 28 [PMID: 22784008], E52862, MR309, sigma 1 receptor antagonist (S1RA) | |||||||
E6201 | 7836 | E 6201, E-6201 | |||||||
ecallantide | 6955 | DX-88, FOV2302, Kalbitor® | |||||||
eculizumab | 6884 | h5G1.1, h5G1.1VHC, Soliris® | |||||||
edicotinib | 8942 | JNJ-40346527, JNJ40346527, US8497376, 15 | |||||||
efalizumab | 6593 | anti alphaL integrin, antiCD11 alpha, hu1124, Raptiva® | |||||||
efgartigimod alfa | 9777 | ARGX-113, efgartigimod alfa-fcab, Vyvgart® | |||||||
efineptakin alfa | 11097 | GX-I7, Hyleukin-7, Il-7 hybrid Fc, NT-I7, rhIL-7-hyFc, TJ-107 | |||||||
efzofitimod | 13199 | ATYR-1923, ATYR1923, KRP-R120 | |||||||
EG01377 | 9904 | (3-((5-(4-(aminomethyl)phenyl)-2,3-dihydrobenzofuran)-7-sulfonamido)thiophene- 2-carbonyl)-L-arginine, compound 1 [PMID: 29648813] | |||||||
eganelisib | 9563 | compound 26 [PMID: 27660692], IPI-549, IPI549 | |||||||
elafin | 12035 | cementoin, trappin-2 | |||||||
eldelumab | 9047 | BMS-936557, MDX-1100 | |||||||
elenestinib | 12357 | BLU-263, BLU263, exampl4 4 [WO2020210293A1] | |||||||
elezanumab | 9290 | ABT-555, AE12-1Y-QL | |||||||
elotuzumab | 8361 | BMS-901608, Empliciti®, HuLuc63 | |||||||
elranatamab | 12889 | elranatamab-bcmm, Elrexfio®, PF-06863135, PF06863135 | |||||||
elsubrutinib | 10464 | example #30 (S) [WO2014210255A1] | |||||||
elubirixin | 8499 | SB 656933, SB-656933, SB656933 | |||||||
emactuzumab | 8944 | RG7155, RO5509554 | |||||||
emapalumab | 9295 | emapalumab-lzsg, Gamifant®, NI-0501, NI0501 | |||||||
emavusertib | 10152 | AU-4948, AU4948, CA4948, compound 24 [PMID: 33335659] | |||||||
emlenoflast | 12172 | Inzomelid, MCC-7840, MCC7840 | |||||||
enexasogaol | 9773 | 6-Shogaol, [6]-shogaol, trans-6-shogaol | |||||||
enoblituzumab | 9589 | MGA-271, MGA271 | |||||||
enokizumab | 8934 | 7F3com-2H2, MEDI-528, MEDI528 | |||||||
enpatoran | 11307 | compound 73 [WO2017106607A1], M-5049, M5049 | |||||||
ensifentrine | 11865 | Ohtuvayre®, RPL554, VMX 554, VMX-554, VMX554 | |||||||
envafolimab | 10492 | Envida®, KN-035, KN035 | |||||||
epacadostat | 8221 | IDO inhibitor 1, INCB 24360, INCB-24360, INCB024360 | |||||||
epcoritamab | 11442 | epcoritamab-bysp, Epkinly®, GEN-3013, GEN3013, Tepkinly® | |||||||
epinastine | 7176 | Elestat®, epinastine hydrochloride | |||||||
epratuzumab | 8088 | 90Y-DOTA-hLL2, 90Y-epratuzumab tetraxetan, 90Y-hLL2, AMG-412, IMMU-hLL2, LymphoCide® (proposed proprietary name) | |||||||
ER-27319 | 9611 | ||||||||
esflurbiprofen | 9420 | (S)-flurbiprofen, BTS-24332, SFPP, TT-063 | |||||||
etanercept | 6789 | Enbrel®, Rhu Tnfr:Fc, TNFR-Fc, TNR 001 | |||||||
etodolac | 7185 | AY-24236, Lodine® | |||||||
etoricoxib | 2896 | Arcoxia®, MK 0663, MK-0663, MK0663 | |||||||
etrasimod | 9331 | APD-334, APD334, APD334-003, compound 4 [PMID: 25516790], Velsipity® | |||||||
etrolizumab | 8407 | PRO145223, RG-7413, RG7413, rhuMAb Beta7 | |||||||
everolimus | 5889 | Afinitor®, Certican®, RAD-001, RAD001, rapamycin, 42-O-(2-hydroxyethyl)-, Zortress® | |||||||
evobrutinib | 9752 | A250 [WO2012170976], M-2951, M2951, MSC 2364447, MSC-2364447C, MSC2364447C | |||||||
example 131 [WO2009133348] | 8489 | ||||||||
example 25 [WO2018228934] | 10201 | ||||||||
example 36 [WO2016177845] | 9555 | ||||||||
Example 4 [WO2017202275A1] | 10449 | ||||||||
F | Back to top | ||||||||
F16357 | 9255 | Compound 39 [PMID: 19791800], Example 1 in WO2007147824 | |||||||
F215 | 10121 | ||||||||
Fas ligand | 5078 | apoptosis antigen ligand, CD95L | |||||||
felzartamab | 13455 | MOR-03087, MOR-202, MOR03087, MOR202 | |||||||
fenebrutinib | 9299 | Example 130 [US20140194408], GDC-0853, GDC0853, RG-7845, RG7845 | |||||||
fenoprofen | 4820 | fenoprofen calcium, Nalfon® | |||||||
fevipiprant | 8995 | NVP-QAW039, QAW039 | |||||||
fexofenadine | 4819 | Allegra®, fexofenadine HCl | |||||||
fezakinumab | 9281 | ILV-094 | |||||||
filgotinib | 7913 | GLPG-0634, GLPG0634, Jyseleca® | |||||||
filgrastim | 6968 | Filcad®, Imumax ®, R-METHUG-CSF | |||||||
fimepinostat | 8952 | CUDC 907, CUDC-907, PI3K/HDAC Inhibitor centn | |||||||
fingolimod | 2407 | FTY-720, FTY720, Gilenya® | |||||||
FIPI | 8781 | compound 14 [PMID: 19136975] | |||||||
firategrast | 11486 | SB-683699, SB683699 | |||||||
fludroxycortide | 7606 | Cordran®, flurandrenolide, flurandrenolone, Haelan® | |||||||
flufenamic acid | 2447 | ||||||||
flumethasone pivalate | 7075 | Locorten® | |||||||
flunisolide | 7076 | AeroBid®, RS-3999 | |||||||
fluocinolone acetonide | 7077 | Capex®, Iluvien®, Synalar® | |||||||
fluocinonide | 7078 | Fluonex®, Lidex® | |||||||
fluorescent MIF ligand B | 9987 | ||||||||
fluorometholone | 7079 | Flarex®, FML® | |||||||
flurbiprofen | 4194 | Ansaid®, Froben® | |||||||
fluticasone | 6699 | Advair®, Avamys®, Flovent HFA®, Veramyst® | |||||||
fluticasone furoate | 10892 | Arnuity Ellipta, Avamys, FF, Flonase Sensimist, Veramyst | |||||||
fluticasone propionate | 7080 | Advair Diskus®, ArmonAir RespiClickTM, CCI-18781, Flovent® | |||||||
fluvoxamine | 7189 | Luvox®, U-23000 | |||||||
FLX475 | 12153 | example 43 [WO2018022992A1], FLX-475 | |||||||
fontolizumab | 9847 | HuZAF | |||||||
formoterol | 3465 | BD-40A, CGP-25827A, Foradil®, Oxeze/Oxis®, YM-08316 | |||||||
forsythoside B | 10303 | ||||||||
fosdagrocorat | 9649 | PF-04171327 | |||||||
fosifidancitinib | 10637 | ||||||||
fostamatinib | 7796 | R 788, R-788, R7935788, Tavalisse®, Tavlesse® | |||||||
FR122047 | 5191 | FR 122047, FR 122047 hydrochloride, FR-122047 | |||||||
friluglanstat | 12888 | example 11 [US9216968B2] | |||||||
G | Back to top | ||||||||
gabapentin | 5483 | CI 945, Go 3450, GOE 2450, GOE 3450, Neurontin® | |||||||
Galapagos MAPKAPK5 inhibitor D | 9848 | compound 183 [WO2007138072A2] | |||||||
galcanezumab | 8967 | clone III, Emgality®, galcanezumab-gnlm, LY-2951742, LY2951742 | |||||||
galectin-1 | 6603 | GBP | |||||||
galectin-3 | 6619 | galectin 3, GALIG, LGALS2, MAC-2 | |||||||
galectin 9 | 9594 | Ecalectin, Gal-9, Tumor antigen HOM-HD-21 | |||||||
galectin-3 binding protein | 6615 | L3 antigen, Mac-2-binding protein, MAC-2-BP | |||||||
gamcemetinib | 12167 | CC-99677, CC99677 | |||||||
gandotinib | 7909 | LY-2784544, LY2784544 | |||||||
GB88 | 6658 | GB 88, GB-88 | |||||||
G-CSF | 4934 | Granocyte® | |||||||
GDC-0214 | 12318 | GDC0214, iJak-381, RG-6151, RG6151 | |||||||
GDC-0834 | 9263 | GDC 0834 | |||||||
GDC-2394 | 12280 | compound 20 [PMID: 36279149], GDC2394 | |||||||
gefapixant | 9540 | AF-219, AF219, Lyfnua®, MK7264, MK‐7264 | |||||||
gemtuzumab ozogamicin | 6775 | CDP 771, CMA 676, hP67.6-calicheamicin, Mylotarg®, WAY-CMA 676 | |||||||
gevokizumab | 7394 | XOMA 052, XOMA-052 | |||||||
gimsilumab | 9624 | MORAb-022 | |||||||
GlcC14C18 | 9483 | 6-O-(2'(R,S)-tetradecyloctadecanoyl)-D-glucose | |||||||
glibenclamide | 2414 | Amglidia®, Diabeta®, glyburide, Glynase® | |||||||
GLP-2 analogue 10 | 9896 | ||||||||
GLPG0974 | 8417 | compound 99 [PMID 25380412] | |||||||
GLPG1205 | 10171 | compound 122 [WO2013092791A1], GLPG-1205 | |||||||
GLPG3970 | 12157 | compound 32 [PMID: 38552030], compound 88 [WO2019238424A1], GLPG-3970 | |||||||
glycopyrrolate | 7459 | AHR-504, Qbrexza® (glycopyrronium cloth), Robinul®, Seebri Neohaler®, Tovanor Breezhaler® | |||||||
GM-CSF | 4942 | colony-stimulating factor, CSF | |||||||
GNE-3500 | 9660 | ||||||||
GNE-4997 | 9995 | compound 28 [PMID: 25844760], GNE 4997, GNE4997 | |||||||
GNE684 | 13107 | GNE-684 | |||||||
GNF362 | 9548 | example 71 [US20090306039] | |||||||
golimumab | 6776 | CNTO-148, CNTO148, Simponi® | |||||||
GPR15L | 10567 | antimicrobial peptide-57, colon-derived SUSD2 binding factor | |||||||
GR-389988 | 10257 | Ex. 3-15 [US9174986B2], GR389988, GZ389988, GZ389988A | |||||||
Grp94 inhibitor 54 | 10118 | ||||||||
GSK065 | 10358 | GSK3335065, inhibitor C1 [PMID: 28604669] | |||||||
GSK143 | 9388 | compound 20 [PMID: 21903390] | |||||||
GSK1482160 | 10504 | compound 1b [PMID: 31525963], compound 31 [PMID: 20673717], GSK-1482160 | |||||||
GSK2245035 | 9254 | compound 32 [PMID: 26861551] | |||||||
GSK2256294 | 9718 | GSK-2256294, GSK-2256294A, GSK2256294A | |||||||
GSK2292767 | 10633 | compound 2 [PMID: 30532965], compound 3 [PMID: 26301626], GSK-2292767 | |||||||
GSK2646264 | 10108 | compound 44 [PMID: 30249354] | |||||||
GSK2879552 | 9116 | Example 26 [WO2012135113], GSK-2879552 | |||||||
GSK2981278 | 9661 | ||||||||
GSK2982772 | 9554 | compound 5 [PMID: 28151659] | |||||||
GSK3050002 | 9623 | E6071, KANAb071 | |||||||
GSK343 | 8240 | compound 6 [PMID 24900432], GSK 343 | |||||||
GSK'547 | 11274 | example 6 [WO2020044206A1], GSK-547, GSK547 | |||||||
GSK583 | 9134 | GSK'583 | |||||||
GSK8612 | 10343 | ||||||||
GSK866 | 9653 | ||||||||
GSK963 | 10132 | GSK'963, GSK′963A | |||||||
GSK2239633A | 10416 | compound 6 [PMID: 23409871], GSK-2239633A | |||||||
GSK-7975A | 10088 | example 36 [US20120053150A1], GSK7975A | |||||||
GSK-J1 | 7027 | ||||||||
GSK-J4 | 8979 | GSK J4, GSKJ4 | |||||||
gusacitinib | 10000 | ASN-002, ASN002, example 189 [WO2013028818A1] | |||||||
guselkumab | 7998 | CNTO-1959, Tremfya® | |||||||
GW274150 | 9849 | [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine, GW-274150 | |||||||
GW3965 | 2754 | C473027, GW 3965, GW-3965 | |||||||
GW406381 | 9850 | compound 8 [PMID: 15454242], GW-406381 | |||||||
GW 627368 | 1953 | GW-627368, GW627368, saccharic acid | |||||||
GW766994 | 9680 | GSK766994, GW-766994 | |||||||
GYY4137 parent molecule | 9808 | GYY4137 | |||||||
H | Back to top | ||||||||
H-151 | 10122 | H 151, H151 | |||||||
H4 antagonist 48 | 9879 | ||||||||
harmine | 9352 | ||||||||
HG-9-91-01 | 8049 | HY-15776 | |||||||
histamine | 1204 | ||||||||
HpARI | 9685 | H. polygyrus Alarmin Release Inhibitor | |||||||
H. polygyrus TGF-β mimic | 9713 | Hp-TGM | |||||||
H2S | 9532 | hydrogen sulfide | |||||||
hsp60 | 4953 | heat shock 60kD protein 1 (chaperonin), HSP-60, mitochondrial matrix protein P1 | |||||||
HsTX1[R14A] | 9582 | KTx 6.3 | |||||||
HTMT | 1273 | histamine-trifluoromethyl-toluidine, histamine-trifluoromethyltoluide, HTFMT | |||||||
hydroxychloroquine | 7198 | Dolquine®, Plaquenil® | |||||||
6-Hydroxy-5,7-dimethoxyflavone | 9878 | UFM-24, UFM24 | |||||||
5-hydroxyindoleacetic acid | 11900 | ||||||||
hydroxyzine | 7199 | Atarax®, hydroxyzine hydrochloride, hydroxyzine pamoate, Vistaril® | |||||||
I | Back to top | ||||||||
ianalumab | 10656 | VAY-736, VAY736 | |||||||
ibalizumab | 10208 | Hu5A8, ibalizumab-uiyk, TMB-355, TMB355, TNX-355, Trogarzo® | |||||||
iberdomide | 9618 | CC-220, compound 6 [PMID: 28425720] | |||||||
iberiotoxin | 4218 | IbTX | |||||||
ibritumomab tiuxetan | 6777 | IDEC-2B8, IDEC-Y2B8-yttrium ibritumomab tiuxetan, NSC-715848, Zevalin® | |||||||
ibrutinib | 6912 | Imbruvica®, PCI-32765 | |||||||
ibudilast | 7399 | AV-411, KC-404, Ketas®, MN-166 | |||||||
ibuprofen | 2713 | Advil®, Brufen®, ibuprofen lysine, ibuprofen sodium, Motrin®, Nurofen®, U-18573 | |||||||
I-C11 | 10374 | ||||||||
IC-87114 | 9376 | IC87114 | |||||||
icanbelimod | 12098 | compound 2 [WO2015039587A1], S1p-receptor-agonist-1, YUN88562 | |||||||
IcatCXPZ-01 | 11179 | compound 8a [PMID: 30978322], XPZ-01 | |||||||
icatibant | 667 | D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]BK, Firazyr®, HOE 140, HOE140 | |||||||
ICOS ligand | 9593 | CD275, B7 homolog 2, B7-H2, B7-related protein 1, B7RP-1, ICOS-L | |||||||
idelalisib | 6741 | CAL-101/CAL101, GS-1101, Zydelig® | |||||||
ifidancitinib | 10638 | A-301, ATI-50002, ATI-502 | |||||||
IFN-α10 | 4956 | IFN alpha-10, interferon alpha-10, interferon alpha-6L, interferon alpha-C | |||||||
IFN-α1/13 | 4955 | IFN-α1, IFN-α13, IFN-alpha 1/13, interferon alpha-1/13, interferon alpha-D | |||||||
IFN-α14 | 4957 | IFN alpha-14, interferon alpha-14, interferon alpha-H, interferon lambda-2-H | |||||||
IFN-α16 | 4958 | IFN alpha-16, interferon alpha-16, interferon alpha-WA | |||||||
IFN-α17 | 4959 | IFN alpha-17, interferon alpha-17, interferon alpha-88, interferon alpha-T | |||||||
IFN-α2 | 4960 | IFN-alpha-2, interferon alpha-2, Roferon A® | |||||||
IFN-α21 | 4961 | IFN-alpha 21, interferon alpha-21, interferon alpha-F | |||||||
IFN-α4 | 4962 | IFN-alpha-4, interferon alpha-4 , interferon alpha-4B, interferon alpha-76, interferon alpha-M1 | |||||||
IFN-α5 | 4963 | IFN-alpha-5, interferon alpha-5, interferon alpha-61, interferon alpha-G | |||||||
IFN-α6 | 4964 | IFN-alpha-6, interferon alpha-54, interferon alpha-6, interferon alpha-K | |||||||
IFN-α7 | 4965 | IFN-alpha-7, interferon alpha-7, interferon alpha-J, interferon alpha-J1 | |||||||
IFN-α8 | 4966 | IFN-alpha-8, interferon alpha-8, interferon alpha-B, interferon alpha-B2 | |||||||
IFN-β | 4967 | Avonex® (recombinant IFN-beta-1a), fibroblast interferon, interferon beta | |||||||
IFN-γ | 4968 | Actimmune®, immune interferon, interferon gamma | |||||||
IFN-κ | 4969 | interferon kappa | |||||||
IFN-λ1 | 4993 | IFN-lambda-1, interferon lambda-1, interferon-λ1, interleukin-29 | |||||||
IFN-λ2 | 4991 | cytokine Zcyto20, IFN-lambda-2, interferon lambda-2, interferon-λ2, interleukin-28A | |||||||
IFN-λ3 | 4992 | cytokine Zcyto22, IFN-lambda-3, IFN-lambda-4, interleukin-28B (IL-28B), interleukin-28C (IL-28C) | |||||||
IFN-ω | 4970 | interferon alpha-II-1, interferon omega-1 | |||||||
IFN-β1b (recombinant human) | 8340 | Betaferon®, Betaseron®, Extavia®, IFNb1b | |||||||
IgE heavy chain | 9557 | ||||||||
iguratimod | 9736 | Careram®, Iremod, Kolbet®, T-614 | |||||||
IKK-beta inhibitor R-28 | 10134 | (R)-28, example 225 [US8372875B2] | |||||||
IKK-2 inhibitor IV | 5986 | TPCA-1, TPCA1 | |||||||
IL-10 | 4975 | interleukin-10 | |||||||
IL-11 | 4976 | interleukin-11 | |||||||
IL-12 | 4977 | IL-12 p70 | |||||||
IL-13 | 4980 | hematopoietic growth factor, interleukin-13, mast cell growth factor, multipotential colony-stimulating factor, P-cell-stimulating factor | |||||||
IL-15 | 4981 | interleukin-15 | |||||||
IL-18 | 4983 | ibocatdekin, interferon-γ-inducing factor, interleukin-1 gamma (IL-1 gamma), interleukin-18 | |||||||
IL-19 | 4984 | interleukin-19, melanoma differentiation-associated protein-like protein | |||||||
IL-1α | 4973 | hematopoietin-1, interleukin-1 alpha | |||||||
IL-1β | 4974 | catabolin, interleukin-1 beta | |||||||
IL-2 | 4985 | aldesleukin, interleukin-2, Proleukin® | |||||||
IL-20 | 4986 | cytokine Zcyto10, interleukin-20 | |||||||
IL-21 | 4987 | interleukin-21, ZA11 | |||||||
IL-22 | 4988 | cytokine Zcyto18, interleukin-22 | |||||||
IL-23 | 4978 | ||||||||
IL-24 | 4990 | interleukin-24, MDA-7, melanoma differentiation-associated gene 7 protein | |||||||
IL-25 | 5876 | IL-17E, interleukin-17E, interleukin-25 | |||||||
IL-27 | 6151 | ||||||||
IL-3 | 4994 | interleukin-3 (IL-3), multilineage-colony-stimulating factor (mCSF) | |||||||
IL-31 | 4995 | interleukin-31 | |||||||
IL-33 | 5880 | IL-1F11 | |||||||
IL-34 | 8975 | ||||||||
IL-36α | 5881 | FIL1 epsilon, interleukin-1 epsilon (IL-1 epsilon) | |||||||
IL-36β | 5882 | FIL1 eta, IL-1 eta, interleukin-1 eta | |||||||
IL-36γ | 5883 | IL-1-related protein 2 (IL-1RP2), interleukin-1 epsilon (IL-1E), interleukin-1 family member 9, interleukin-36 gamma | |||||||
IL-37 | 6149 | IL-1ζ, IL-23, interleukin-1ζ, interleukin-1-related protein (IL1RP), interleukin-23 | |||||||
IL-4 | 4996 | B-cell stimulatory factor 1, binetrakin, interleukin-4, pitrakinra | |||||||
IL-5 | 4997 | ||||||||
IL-6 | 4998 | B-cell stimulatory factor 2, CTL differentiation factor, hybridoma growth factor, interferon β2, interleukin-6 | |||||||
IL-7 | 4999 | interleukin-7 | |||||||
IL-9 | 5000 | interleukin-9 | |||||||
IL-12A | 5001 | IL-12 p35, interleukin-12A, NKSF1 | |||||||
IL-17A | 4982 | CTLA-8, interleukin-17 alpha | |||||||
IL-23A | 4989 | IL-23p19, IL23A, interleukin-23 subunit alpha, interleukin-23A | |||||||
IL-17A/IL-17F | 5874 | ||||||||
IL-12B | 5002 | IL-12 p40, IL-12B monomer, interleukin-12β, interleukin-12B, natural killer cell stimulatory factor 2 | |||||||
IL-17B | 5877 | ||||||||
IL-17C | 5875 | cytokine CX2, interleukin-17C | |||||||
IL-17F | 5873 | cytokine ML-1, Interleukin-17F | |||||||
iloprost | 1895 | Aurlumyn®, Ventavis® | |||||||
IL-1 receptor antagonist | 5878 | IL-1ra, interleukin-1 receptor antagonist protein, IRAP | |||||||
IL-36 receptor antagonist | 5879 | IL-1 related protein 3 (IL1RP3), IL-1F5, IL-36ra, IL1F5, interleukin 1 family member 5 (delta) | |||||||
IL-27 subunit α | 6152 | IL-27 subunit alpha, interleukin-27 subunit alpha, p28 | |||||||
IL-27 subunit β | 6153 | EBV-induced gene 3 protein, Epstein-Barr virus-induced gene 3 protein, IL-27 subunit beta, IL-27B, interleukin-27 subunit beta | |||||||
imaprelimab | 9805 | PRX-003, PRX003 | |||||||
imaradenant | 11153 | AZD-4635, AZD4635 | |||||||
imatinib | 5687 | CGP 57148, Gleevec®, Glivec®, STI571 | |||||||
imetit | 1250 | ||||||||
imiquimod | 5003 | Aldara®, R837, S-26308, Zyclara® | |||||||
immepip | 1251 | ||||||||
impromidine | 1226 | SK&F-92676-A3 | |||||||
INCB3284 | 9045 | compound 13 [PMID: 24900329], INCB 3284 | |||||||
INCB8761 | 9032 | compound 17 [PMID: 24900280], INCB-8761, PF-4136309, PF4136309 | |||||||
inclacumab | 12312 | HuMab 002, LC1004-002, RO-4905417, RO4905417 | |||||||
indacaterol | 7455 | Arcapta Neohaler®, Onbrez®, QAB-149, QAB149 | |||||||
indole-3-carbinol | 10047 | 3-hydroxymethylindole, 3-indolemethanol, 3-indolylcarbinol, I3C | |||||||
indomethacin | 1909 | Indocid®, Indocin® | |||||||
infliximab | 5004 | cA2, Inflectra®, Remicade®, Remsima®, SB2, TA-650, Zymfentra® (subcutaneous formulation) | |||||||
inhibitor M9 [PMID: 38236416] | 13113 | ||||||||
inhibitor 32 [PMID: 29620892] | 9898 | ||||||||
inotuzumab ozogamicin | 8266 | Besponsa®, CMC-544 | |||||||
ipilimumab | 6888 | MDX-010, MDX-101, MDX-CTLA-4, Yervoy® | |||||||
ipratropium | 325 | Atrovent®, Ipraxa® | |||||||
iptacopan | 10710 | compound 41 [PMID: 32073845], Fabhalta®, LNP-023, LNP023 | |||||||
IRAK-1/4 inhibitor | 5990 | ||||||||
IRAK4 inhibitor 4b [PMID: 18474425] | 8080 | ||||||||
IRAK4 inhibitor rac-45 [PMID: 18501603] | 8081 | ||||||||
ISO-1 | 9984 | IN1228 | |||||||
isoetarine | 7205 | Bronkometer®, Bronkosol®, WIN-3406 | |||||||
isothiourea-1t | 2899 | IT1t | |||||||
isunakinra | 9704 | EBI-005 | |||||||
itacitinib | 8364 | Examlpe 294 [WO2011112662], INCB-039110 | |||||||
itolizumab | 9421 | Alzumab®, T1h | |||||||
ivarmacitinib | 11878 | example 34 [WO2013091539A1], SHR-0302, SHR0302 | |||||||
ivonescimab | 13396 | AK-112, AK112, Idafang® (China), SMT-112, SMT112 | |||||||
ixekizumab | 7541 | LY-2439821, LY2439821, Taltz® | |||||||
izencitinib | 10458 | example 1 [WO2016191524A1], JNJ-8398, JNJ8398, TD-1473, TD1473 | |||||||
J | Back to top | ||||||||
JAK3 inhibitor 32 | 10156 | compound 32 [PMID: 30423248] | |||||||
JAK3 inhibitor 34 | 10157 | compound 34 [PMID: 30423248] | |||||||
JAK inhibitor 20a | 10147 | ||||||||
JAK inhibitor 17b | 10148 | ||||||||
JNJ-10191584 | 1277 | compound 12, JNJ 10191584, VUF 6002, VUF6002 | |||||||
JNJ-10311795 | 6563 | ||||||||
JNJ-27141491 | 10586 | JNJ27141491 | |||||||
JNJ-39758979 | 8984 | JNJ 39758979, JNJ39758979 | |||||||
JNK inhibitor IX | 5996 | AC1LG8KT, BAS 01816608, TCS JNK 5a | |||||||
JR14a | 10595 | ||||||||
K | Back to top | ||||||||
KA1010 | 9663 | ||||||||
KBP-7018 | 9691 | compound 3 [Huang et al., 2017] | |||||||
ketoprofen | 4795 | Actron®, Orudis® | |||||||
ketorolac | 6661 | Acular®, Toradol® | |||||||
KML29 | 9482 | ||||||||
KT-109 | 10245 | KT109 | |||||||
KT-474 | 12892 | Compound A [WO2022174269A1], KT474 | |||||||
L | Back to top | ||||||||
L-798,106 | 1941 | L-798106, L798106 | |||||||
labuxtinib | 12870 | Compound 1 [WO2022109595], example F91 [WO2013033070] | |||||||
lanraplenib | 9764 | compound 39 [PMID: 32292557], Ex.-2, US9290505, example 2 [US9290505], GS-9876, GS9876 | |||||||
Large proline-rich protein BAG6 | 11143 | BAG6 | |||||||
LASSBio-1524 | 11066 | ||||||||
LASW1393 | 10527 | compound 34 [PMID: 31609613], LASW-1393 | |||||||
lazucirnon | 10653 | AKST-4290, AKST4290, ALK-4290, ALK4290, Example 11 [WO2012045803A1] | |||||||
lebrikizumab | 7684 | Ebglyss®, lebrikizumab-lbkz, MILR1444A, RG3637, TNX-650 | |||||||
leflunomide | 6825 | Arabloc®, Arava®, HWA 486, HWA-486, lefunamide, SU-101 | |||||||
lenabasum | 9772 | ajulemic acid, CPL-7075, CPL7075, CT-3, IP-751, IP751 | |||||||
lenalidomide | 7331 | CC-5013, CDC-501, Revlimid® | |||||||
leniolisib | 9424 | CDZ-173, CDZ173, Example 67 [WO2012004299], Joenja® | |||||||
lenzilumab | 8935 | KB-003, KB003 | |||||||
LEO 134310 | 11901 | LEO-134310, LEO134310 | |||||||
LEO 239652 | 12725 | compound 40 [PMID: 33054196], LEO-239652, LEO239652 | |||||||
LEO 29102 | 12724 | compound 20 [PMID: 24984230], LEO-29102, LEO29102 | |||||||
L-161,982 (EP4A) | 1952 | EP4A, L-161982, L161982 | |||||||
lepzacitinib | 12871 | example 117 [WO2019090158A1] | |||||||
leronlimab | 10752 | PRO 140, PRO-140, PRO140, Vyrologix® | |||||||
lestaurtinib | 5672 | CEP-701, KT-5555, SP924 | |||||||
levosalbutamol | 9816 | (-)-albuterol, (-)-salbutamol, (R)-salbutamol, levalbuterol, Xopenex® | |||||||
LFM-A13 | 9262 | α-cyano-beta-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide, alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide | |||||||
L6H21 | 9027 | ||||||||
LHVS | 9298 | morpholinurea-leucine-homophenylalanine-vinylsulfone-phenyl, morpholinurea-leucine-homophenylalaninevinyl phenyl sulfone | |||||||
LIF | 5016 | cholinergic differentiation factor (CDF), differentiation-inducing factor (DIF), human interleukin in DA cells (HILDA) | |||||||
lifitegrast | 7533 | compound 1g [PMID: 24900456], SAR 1118, SAR-1118, SAR-1118-023, Xiidra® | |||||||
ligelizumab | 8997 | CL-2C, NVP-QGE031, QGE031 | |||||||
LIGHT | 5070 | Herpesvirus entry mediator-ligand, TR2 | |||||||
lilotomab | 9950 | Betalutin®, HH1, tetulomab | |||||||
linrodostat | 9707 | BMS-986205, BMS986205, Compound 2 [PMID: 29531094], Example 19 [US20160137652A1] | |||||||
lintuzumab | 7983 | ACTIMAB®, HuM195, SGN-33, SMART M195 | |||||||
(S)-liquiritigenin | 8899 | ||||||||
lirilumab | 9310 | 1-7F9, BMS-986015, IPH2102 | |||||||
lisofylline | 9225 | (R)-lisophylline, CT-1501R | |||||||
LIT-927 | 10075 | compound 57 [PMID: 30106292] | |||||||
litifilimab | 11122 | BIIB-059, BIIB059 | |||||||
liver enriched antimicrobial peptide 2 | 9734 | LEAP2 | |||||||
LL-37 | 5527 | antibacterial protein LL-37, cathelicidin LL 37 (human) | |||||||
LM10 | 9016 | LM-10 | |||||||
lodoxamide | 9743 | Alomide® | |||||||
lomedeucitinib | 13210 | BMS-986322, BMS986322, example 252 [US20210253554] | |||||||
londamocitinib | 11716 | AZD-4604, AZD4604, example 35 [WO2018134213A1], Jak1-IN-7 | |||||||
lonodelestat | 11275 | cyclo[Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-D-Pro-Pro-Nle(Bu)-Glu-Thr], POL-6014, POL6014 | |||||||
loratadine | 7216 | Claritin®, SCH-29851 | |||||||
lorecivivint | 9620 | adavivint (deprecated INN), SM0-4690, SM04690 | |||||||
losmapimod | 7835 | GS856553, GW856553 | |||||||
loteprednol etabonate | 7085 | HGP-1, Inveltys®, Lotemax®, P-5604 | |||||||
lovastatin | 2739 | (+)-mevinolin, 6α-methylcompactin, Mevacor® | |||||||
5-LOX activating protein | 5183 | FLAP, 5-lipoxygenase-activating protein, arachidonate 5-lipoxygenase-activating protein | |||||||
5-LOX inhibitor 2m [PMID: 30199704] | 10079 | ||||||||
LTB4 | 2487 | leukotriene B4 | |||||||
lulizumab pegol | 8460 | BMS-931699, BMS931699 | |||||||
lumiracoxib | 2897 | Prexige® | |||||||
lutikizumab | 9297 | ABT-981, E26.13-SS-X3 | |||||||
LW106 | 9940 | ||||||||
LX2931 | 9851 | LX3305 | |||||||
LXB4 | 5216 | lipoxin B4 | |||||||
LY255283 | 3351 | CGS 23356, LY 255283, LY-255283 | |||||||
LY3022855 | 9109 | IMC-CS4 | |||||||
LY3023703 | 12211 | compound 9 [PMID: 25260492] | |||||||
LY3509754 | 13164 | ||||||||
lymphotoxin-α | 5064 | TNFSF1, LTα, TNFβ | |||||||
LYS006 | 11205 | LYS-006 | |||||||
M | Back to top | ||||||||
3M-002 | 9270 | CL-075, CL075 | |||||||
MAB92 | 9665 | ||||||||
macrophage migration inhibitory factor | 9981 | L-dopachrome isomerase, MMIF | |||||||
magrolimab | 12652 | Hu5F9-G4 | |||||||
MAPK13-IN-1 | 11096 | compound 61 [WO2014015056A2] | |||||||
mapracorat | 9654 | BOL-303242-X, ZK-245186, ZK245186 | |||||||
maraviroc | 806 | Celsentri®, Selzentry®, UK 427857, UK-427,857 | |||||||
marbostat-100 | 9891 | compound 5a [PMID: 29589441] | |||||||
maresin 1 | 12056 | 7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid, 7R-Maresin 1, MaR1, Maresin-1 | |||||||
maresin 2 | 12055 | 13R,14S-diHDHA, 13R,14S-dihydroxy-docosahexaenoic acid, MaR2, maresin-2 | |||||||
masitinib | 5656 | AB-1010, AB1010, Masican® (proposed trade name) | |||||||
mavorixafor | 8580 | AMD 070, AMD-070, AMD-11070, AMD11070, compound 2 [PMID: 20297846], X4P-001, X4P-001-IO, X4P-001-LD, Xolremdi® | |||||||
mavrilimumab | 7785 | CAM-3001, KPL-301 | |||||||
MCC950 | 8228 | CP-456,773, CP-456773, CRID3, MCC-950 | |||||||
MCS110 | 9110 | ||||||||
M-CSF | 4905 | CSF-1, lanimostim, macrophage-CSF | |||||||
MDG 548 | 9888 | compound 1 [PMID: 22582973], MDG-548, MDG548 | |||||||
meclofenamic acid | 7219 | CL-583, INF-4668, Meclomen® | |||||||
medrysone | 7086 | U-8471 | |||||||
mefenamic acid | 2593 | CI-473, CN-35355, INF-3355, Ponstan®, Ponstel® | |||||||
melatonin | 224 | MLT, Circadin® | |||||||
meloxicam | 7220 | Mobic®, UHAC-62XX | |||||||
mepacrine | 10172 | Atabrine®, quinacrine | |||||||
mepolizumab | 7685 | Nucala®, SB-240563 | |||||||
mepyramine | 1227 | Anthisan®, mepiramine, mepyramine maleate, pyrilamine, pyrilamine tannate, Pyrlex® | |||||||
merestinib | 9841 | LY-2801653, LY2801653 | |||||||
mesalazine | 2700 | 5-aminosalicylic acid, 5-ASA, mesalamine (USAN), Pentasa® | |||||||
[Met]enkephalin | 1614 | 1-5 Adrenorphin, [Met]-enkephalin, IRT-101, methionine enkephalin, np2 enkephalin, opioid growth factor (OGF) | |||||||
metformin | 4779 | Glucophage®, LA-6023 | |||||||
methacholine | 7438 | methacholine bromide, Provocholine® | |||||||
methimazole | 6649 | Tapazole®, Thiamazole® | |||||||
methotrexate | 4815 | Abitrexate®, amethopterin, Nordimet®, Rasuvo® | |||||||
(R)-α-methylhistamine | 1236 | (R)-α-MeHA, alpha-methylhistamine | |||||||
methylprednisolone | 7088 | Medrol®, U-67590A | |||||||
mezagitamab | 10609 | TAK-079, TAK079 | |||||||
MIDD0301 | 9890 | ||||||||
midostaurin | 5702 | CGP 41231, CGP 41251, N-benzoylstaurosporine, PKC412, Rydapt® | |||||||
mifepristone | 2805 | Mifeprex®, RU-486, RU486 | |||||||
MIF inhibitor 3bb | 9986 | ||||||||
milategrast | 10463 | example 9 [US20050261291A1] | |||||||
milatuzumab | 8267 | hLL1, IMMU-115 | |||||||
miltefosine | 11355 | D-18506, D18506, Impavido®, Miltex®, n-hexadecylphosphorylcholine | |||||||
mirikizumab | 9846 | Antibody I [US9023358], LY-3074828, LY3074828, mirikizumab-mrkz, Omvoh® | |||||||
mivavotinib | 9600 | compound 3b [PMID: 27839918], TAK-659, TAK659 | |||||||
mizolastine | 10102 | Mizollen®, MKC-431, MKC431, SL 85.0324, SL-850324, SL850324 | |||||||
MK-0359 | 9852 | L-454,560, L-454560, MK0359 | |||||||
MK-0812 | 9048 | MK0812 | |||||||
MK-0873 | 9853 | compound 20 [PMID: 18835163], MK0873 | |||||||
MK-7110 | 11395 | CD24-Fc, CD24Fc | |||||||
MK-886 | 2655 | L 663536, MK886 | |||||||
ML130 | 8887 | compound 1c [PMID: 22003428], ML-130, Noditinib-1 | |||||||
ML324 | 9584 | ML-324, MMV1580488 | |||||||
MLN-120B | 5694 | ML120B, MLN120B | |||||||
ML2-SA1 | 10301 | EVP-22, EVP22, ML2 SA1, ML2SA1 | |||||||
MM-433593 | 9944 | MM433593 | |||||||
MMK-1 | 6240 | MMK 1 | |||||||
mocravimod | 9727 | compound 2 [PMID: 23124563], KRP-203, KRP203 | |||||||
mocravimod-phosphate | 2923 | KRP 203-phosphate, KRP203-phosphate | |||||||
mofegiline | 9754 | MDL 72974, MDL-72,974, MDL-72974A | |||||||
mogamulizumab | 6477 | KW-0761, mogamulizumab-kpkc, Poteligeo® | |||||||
molibresib | 7033 | CS-0717, GSK 525762A, GSK-525762, GSK525762, I-BET-762, I-BET762 | |||||||
mometasone | 9029 | Elocon® (topical), Nasonex® | |||||||
monalizumab | 8323 | humZ270, IPH-2201, NN8765-3658 | |||||||
mongersen | 8277 | DNA, d(P-thio)(G-T-m5C-G-C-C-C-C-T-T-C-T-C-C-C-m5C-G-C-A-G-C), GED-0301, GED0301 | |||||||
monomethyl fumarate | 5786 | methyl hydrogen fumarate | |||||||
montelukast | 3340 | Singulair® | |||||||
mosedipimod | 9771 | EC-18, Plag, (+/-) | |||||||
motixafortide | 10679 | 4F-Benzoyl-TN14003, Aphexda®, BKT140, BL-8040, TF14016 | |||||||
motolimod | 9026 | VTX-2337 | |||||||
moxetumomab pasudotox | 7675 | CAT-8015, GCR-8015, HA22, Lumoxiti®, moxetumomab pasudotox-tdfk | |||||||
MPI-0485520 | 9580 | MPC-9528, MPI-485520 | |||||||
MPPA | 9897 | inhibitor 23 [PMID: 29614224] | |||||||
MRI-1867 | 10521 | (-)-MRI-1867, MRI1867 | |||||||
MRL-248 | 9080 | ||||||||
MRL-367 | 9079 | ||||||||
MRL-871 | 10642 | MRL871 | |||||||
MRS2578 | 1753 | MRS 2578, MRS-2578 | |||||||
MRS4458 | 9998 | compound 20 [Yu et al., 2018] | |||||||
MRS4478 | 9999 | compound 30 [Yu et al., 2018] | |||||||
MRT67307 | 8062 | MRT-67307 | |||||||
mucosal addressin cell adhesion molecule 1 | 9339 | MAdCAM-1, addressin, MAdCAM1 | |||||||
muromonab-CD3 | 6889 | L04AA02, OKT-3, Orthoclone Okt3® | |||||||
MW150 | 10524 | compound 11 [PMID: 30978288], compound 27 [WO2014145485A2], compound 8 [PMID: 25676389], MW-150, MW01-18-150SRM | |||||||
mycophenolate mofetil | 6831 | Cellcept®, RS-61443, RS-61443-190 | |||||||
N | Back to top | ||||||||
nabumetone | 7245 | BRL-14777, Relafen® | |||||||
nacresertib | 13502 | compound 001 [WO2021057785] | |||||||
namilumab | 10370 | AMG203, MT203 | |||||||
naproxcinod | 9551 | AZD-3582, AZD3582, HCT-3012, NO-naproxen | |||||||
naproxen | 5230 | (S)-naproxen, Aleve®, Naprosy® | |||||||
naptumomab estafenatox | 9948 | ABR-217620, ABR217620, Anyara (proposed trade name), TTS CD3, TTS-CD3 | |||||||
naratuximab emtansine | 9949 | IMGN-529, IMGN529, K7153A-SMCC-DM1 | |||||||
natalizumab | 6591 | AN100226, anti-alpha4 integrin, anti-VLA4, Tysabri® | |||||||
Natural cytotoxicity triggering receptor 3 ligand 1 | 11142 | B7H6, B7-H6 | |||||||
navamepent | 9463 | RX-10045 | |||||||
navarixin | 8497 | MK-7123, MK7123, SCH-527123, SCH527123 | |||||||
navoximod | 9019 | GDC-0919, NLG-919, NLG919, RG6078 | |||||||
NBI-74330 | 839 | (±)-NBI 74330, NBI74330 | |||||||
NC1 | 10373 | ||||||||
NCX-4016 | 9018 | NCX 4016, NCX4016, nitric oxide-releasing aspirin, nitroaspirin | |||||||
ND-2110 | 8082 | ||||||||
ND-2158 | 8083 | ||||||||
NDT-19795 | 13009 | NDT19795 | |||||||
NDT9513727 | 9746 | NDT 9513727, NDT-9513727 | |||||||
necrostatin-1 | 9750 | methyl-thiohydantoin-tryptophan, MTH-DL-tryptophan, MTH-trp, nec-1, Necrostatin 1 | |||||||
necrostatin-1s | 9751 | 7-Cl-O-Nec-1, nec-1s, necrostatin 2 racemate | |||||||
nedocromil | 7607 | FPL-59002, nedocromil sodium, Rapitil®, Tilade® | |||||||
neflamapimod | 5719 | VD-31745, VRT-031745, VX 745, VX-745 | |||||||
nemiralisib | 9425 | compound 2 [PMID: 26301626], GSK-2269557, GSK2269557 | |||||||
nemolizumab | 8720 | CD14152, CIM 331, CIM331, Mitchga®, Nemluvio® | |||||||
neoceptin-3 | 9137 | ||||||||
neoceptin-4 | 9138 | ||||||||
NE 52-QQ57 | 10206 | example 35 [WO2012131633A1], GPR4 antagonist 13, NE52-QQ57 | |||||||
nerandomilast | 12518 | BI 1015550, BI-1015550, BI1015550 | |||||||
α-NETA | 9781 | ||||||||
Nexinhib20 | 9419 | ||||||||
nezulcitinib | 11304 | example 1 [WO2020051105A1] | |||||||
NF-56-EJ40 | 10519 | ||||||||
nibrozetone | 13184 | ABDNAZ, RRx-001, RRx001 | |||||||
niflumic acid | 2439 | ||||||||
NIK inhibitor 12f | 10947 | ||||||||
NIK SMI1 | 9964 | ||||||||
nimesulide | 7401 | R-805 | |||||||
nivolumab | 7335 | BMS-936558, MDX-1106, ONO-4538, Opdivo® | |||||||
N-methyl-2-pyrrolidone | 9520 | NMP, N-methyl-pyrrolidone | |||||||
6-n-octylaminouracil | 5846 | 6-n-octyl aminouracil | |||||||
NPT520-34 | 13271 | compound 1 [WO2019246454] | |||||||
NS-398 | 8976 | NS 398 | |||||||
NS6180 | 9318 | ||||||||
NS6740 | 11383 | A-793394, A793394, NS-6740 | |||||||
NSC61610 | 10364 | ||||||||
NSC80734 | 10497 | ||||||||
NT-0249 | 13338 | NT0249 | |||||||
NT-0796 | 13008 | NT0796 | |||||||
nurulimab | 12992 | BCD-145, BCD145 | |||||||
NX-2127 | 12519 | ||||||||
NX-5948 | 12898 | compound 195 [WO2021113557A1], NX5948 | |||||||
O | Back to top | ||||||||
obatoclax | 11086 | GX-15-070, GX15-070, obatoclax mesylate, SB16622 | |||||||
obinutuzumab | 6941 | GA-101, GA101, Gazyva® | |||||||
ocadusertib | 13504 | compound I-30 [WO2021046407], LY-3871801, LY3871801, R-552, R552 | |||||||
oclacitinib | 9696 | Apoquel® (veterinary use), PF-03394197 | |||||||
ocrelizumab | 7580 | 2H7, Ocrevus®, PRO70769, RG1594 | |||||||
17-octadecynoic acid | 8851 | 17-ODYA | |||||||
OD36 | 10406 | ||||||||
ofatumumab | 6778 | Arzerra®, GSK 1841157, GSK1841157, humax-CD20, Kesimpta® (subcutaneous), OMB-157, OMB157 | |||||||
ofirnoflast | 13227 | example 10 [WO2021242505] | |||||||
olamkicept | 9729 | FE 999301, FE-301, FE-999301, TJ301 | |||||||
olaptesed pegol | 9674 | NOX-A12 | |||||||
oleclumab | 9596 | MEDI 9447, MEDI-9447 | |||||||
olinciguat | 10213 | IW-1701, IW1701 | |||||||
olodaterol | 7543 | BI-1744, BI-1744-CL, Striverdi® | |||||||
olopatadine | 7249 | ALO-4943A, KW-4679, Opatanol®, Patanol®, Pazeo® | |||||||
olverembatinib | 10630 | compound 10a [PMID: 23301703], GZD-824, GZD824, HQP-1351, HQP1351 | |||||||
omalizumab | 6890 | IGE25, olizumab, R03DX05, RG-3648, rhumab-E25, Xolair® | |||||||
omaveloxolone | 7573 | RTA 408, RTA-408, Skyclarys® | |||||||
4-OMe-ARM1 | 10562 | compound 7 [PMID: 31751136] | |||||||
omilancor | 10363 | analogue 7 [PMID: 27933891], BT-11, BT11, Example 1 [US9556146B2] | |||||||
omipalisib | 8974 | GSK 2126458, GSK-2126458, GSK2126458 | |||||||
ONC201 | 9978 | ONC-201, TIC-10, TIC10 | |||||||
onfekafusp alfa | 9757 | Fibronum, L19TNF-alpha | |||||||
ONO-AE3-208 | 1942 | ONO AE3 208 | |||||||
ontamalimab | 9340 | PF-00547659, PF-547659, SHP647 | |||||||
ONX-0914 | 9031 | PR-957 | |||||||
oprelvekin | 6971 | Neumega® | |||||||
ordesekimab | 13046 | AMG-714, AMG714, MAb146B7, PRV-015 | |||||||
orelabrutinib | 10629 | example 3 [WO2015048662A2], ICP-022, ICP022 | |||||||
ORG 214007-0 | 11310 | [(-)-N-(2S,10S,14bS)]-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyl dibenzo[c,f]pyrido[1,2-a]azepin-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide]], ORG214007-0 | |||||||
Orita-13 | 9985 | compound 13 [PMID: 11170644] | |||||||
oroxylin A | 13522 | ||||||||
OSE-127 | 9604 | Effi-7 | |||||||
osthole | 10302 | 7-Methoxy-8-isopentenylcoumarin, osthol | |||||||
otenaproxesul | 9534 | ATB 346, ATB-346, ATB-346, (S)-, ATB346 | |||||||
otilimab | 11132 | GSK-3196165, GSK3196165, MOR-103, MOR103 | |||||||
otlertuzumab | 9951 | CD37-SMIP, TRU-016, TRU016 | |||||||
oxaprozin | 7252 | Daypro®, WY-21743 | |||||||
OX-40 ligand | 5076 | glycoprotein Gp34, TXGP-1 | |||||||
ozagrel | 9866 | Cataclot®, KCT-0809, OKY-046, Pulmoza® | |||||||
ozanimod | 8709 | RPC-1063, RPC1063, Zeposia® | |||||||
ozoralizumab | 9638 | ATN-103, PF-5230896 | |||||||
P | Back to top | ||||||||
P505-15 | 8070 | BIIB057, PRT-062607, PRT062607 | |||||||
PAF | 1831 | PAF (C16), PAF C-16, platelet activating factor | |||||||
pamapimod | 9915 | compound 2b [PMID: 21375264], Ro 4402257, Ro-4402257, Ro4402257 | |||||||
Pam2CSK4 | 8560 | ||||||||
Pam3CSK4 | 8558 | ||||||||
parecoxib | 2895 | Dynastat®, SC-69124 | |||||||
parsaclisib | 10098 | compound 20 [PMID: 31749910], IBI376, INCB-050465 | |||||||
pascolizumab | 7786 | SB-240683 | |||||||
pateclizumab | 9854 | MLTA3698A, PRO283698, RG7416 | |||||||
PBF-509 | 10193 | PBF509 | |||||||
PBT-3 | 9755 | ||||||||
PCA 4248 | 6080 | PCA-4248, PTEMC | |||||||
pCXCL8-1aa | 9938 | ||||||||
PDE4 inhibitor 16 | 10400 | ||||||||
pecazine | 9782 | mepazine, nothiazine, Pacatal | |||||||
peficitinib | 8315 | ASP015K, JNJ-54781532 | |||||||
peginterferon alfa-2b | 7462 | PegIntron®, Sylatron® | |||||||
peginterferon beta-1a | 7637 | interferon beta 1-alpha, PEG-INF-β-1a, Plegridy® | |||||||
pelubiprofen | 9876 | compound 13b [PMID: 6607354], CS-670, DW-330SR, DW330SR, RS-2131 | |||||||
pembrolizumab | 7499 | Keytruda®, lambrolizumab, MK-3475 | |||||||
penicillamine | 7264 | Cuprimine® | |||||||
penpulimab | 12347 | AK-105, AK105 | |||||||
peptide Cp40 [PMID: 25982307] | 9220 | peptide 14 | |||||||
peptide 1 [PMID: 31774287] | 10594 | ||||||||
peptide 30 [PMID: 27019010] | 9253 | ||||||||
perenostobart | 12103 | SRF-617, SRF617 | |||||||
petesicatib | 9855 | RG-7625, RG7625, RO-5459072 | |||||||
PF-03715455 | 8179 | ||||||||
PF-04191834 | 9054 | PF 4191834, PF-4191834 | |||||||
PF-04418948 | 5817 | PF 04418948, PF04418948 | |||||||
PF-04634817 | 9979 | example 13 [US8293903], PF-4634817, PF04634817, PF4634817 | |||||||
PF-04859989 | 9038 | compound 1 [PMID: 23466229] | |||||||
PF-04905428 | 9062 | CE-224,535, CE-224535, compound 3 [PMID: 21782426], compound 33 [PMID: 21565499] | |||||||
PF-04957325 | 9659 | ||||||||
PF-06263276 | 9432 | compound 2 [PMID: 27983835], PF 0626327, PF0626327 | |||||||
PF-06282999 | 10053 | compound 8 [PMID: 26509551], PF06282999 | |||||||
PF-06426779 | 9666 | example 189 [WO2015150995], example 38 [PMID:28498658] | |||||||
PF-06840003 | 9565 | EOS200271, PF06840003 | |||||||
PF‐06928215 | 11324 | ||||||||
PF-07038124 | 11950 | Example 4 [US2020108083A1], PF07038124 | |||||||
PF-07054894 | 12765 | PF07054894 | |||||||
PF-152 | 9014 | compound 43a, example 64 [WO2009016498], PF152 | |||||||
PFK15 | 9562 | PFK-015 | |||||||
PGE2 | 1883 | Cervidil®, minprositin E2, minprostin E2, Propess®, prostaglandin E2 | |||||||
PGF2α | 1884 | prostaglandin F2α | |||||||
PH-797804 | 7818 | ||||||||
PHA-408 | 9398 | PHA408 | |||||||
phenylbutazone | 7270 | Butazolidine® | |||||||
piclamilast | 11627 | RP 73401, RP-73-401, RP73401 | |||||||
piclidenoson | 422 | IB-MECA, CF 101, CF101, N(6)-ibamu | |||||||
pirfenidone | 7532 | AMR-69, Esbriet® | |||||||
piroxicam | 7273 | CP-16171, Feldene® | |||||||
pirtobrutinib | 11628 | BTK inhibitor 16, Jaypirca®, LOXO-305, LOXO305, MCL-133, MCL133, RXC005 | |||||||
pixatimod | 9870 | compound 18 [PMID: 22458531], PG-545, PG545 | |||||||
PJ34 | 11348 | PJ-34 | |||||||
PKCθ inhibitor 14 | 9452 | compound 14 [PMID: 27117263] | |||||||
PKUMDL_MH_1001 | 9141 | ||||||||
plerixafor | 844 | AMD 3100, AMD3100, bicyclam JM-2987, JM 3100, Mozobil® | |||||||
plonmarlimab | 11644 | TJ 003234, TJ003234, TJM2 | |||||||
plozalizumab | 8921 | hu1D9, MLN-1202, MLN1202 | |||||||
PLX5622 | 9105 | PLX 5622, PLX-5622 | |||||||
PLX7486 | 9104 | OPN 7486, OPN-7486, PLX-7486 | |||||||
(S)-23 [PMID: 27933945] | 9796 | ||||||||
PMX205 | 5762 | ALS-205, PMX 205, PMX-205 | |||||||
PN10 | 10089 | ||||||||
PO-322 | 10739 | 1H-indole-2,3-dione 3-(1,3-benzoxazol-2-ylhydrazone), PO322 | |||||||
polatuzumab vedotin | 8404 | ACD79B-VCMMAE, polatuzumab vedotin-piiq, Polivy®, RG-7596, RG7596, RO5541077-000 | |||||||
polmacoxib | 8316 | Acelex® (S. Korea), CG-100649, CG100649 | |||||||
pomalidomide | 7348 | CC-4047, IMID-3, Imnovid®, Pomalyst® | |||||||
POM2-C-HMBP | 9616 | ||||||||
ponatinib | 5890 | AP24534, Iclusig® | |||||||
ponesimod | 9320 | ACT-128800, ACT128800, Compound 8bo [PMID:20446681], Ponvory® | |||||||
poseltinib | 9862 | Example 228 [WO2011162515A2], HM71224, HM‐71224, LY333764 | |||||||
povorcitinib | 11881 | compound 7 [US20210238168A1] | |||||||
pozelimab | 12900 | pozelimab-bbfg, REGN-3918, REGN3918, Veopoz® | |||||||
PP2 | 9404 | ||||||||
PQA-18 | 9454 | ||||||||
praliciguat | 9900 | IW-1973, IW1973 | |||||||
pralnacasan | 6467 | VX-740, VX740 | |||||||
pranlukast | 3634 | ONO RS-411 | |||||||
prednicarbate | 7605 | Dermatop®, Hoe 777, Hoe-777, S-770777 | |||||||
prednisolone | 2866 | DELTA.1-Cortisol, Orapred®, Pediapred® | |||||||
prednisone | 7096 | Lodotra®, Sterapred® | |||||||
preladenant | 5614 | SCH-420814, SCH420814 | |||||||
PRN694 | 9285 | ||||||||
procaterol | 3464 | ||||||||
programmed cell death 1 ligand 1 | 9606 | PD-L1, B7 homolog 1, B7-H1, PDL1, programmed death ligand 1 | |||||||
prolgolimab | 12991 | BCD-100, BCD100 | |||||||
PSB1115 | 3286 | compound 17 [PMID: 11906291], PSB 1115, PSB-1115 | |||||||
PSB-17365 | 9871 | compound 48 [Pillaiyar et al., 2018], PSB17365 | |||||||
PSB-KD107 | 11081 | compound 2Ak [PMID: 17827019], compound 5 [Schoeder et al., 2020] | |||||||
psora-4 | 9583 | 5-(4-phenylbutoxy)psoralen, psora 4 | |||||||
PXS-4681A | 9753 | ||||||||
PXS-4728A | 9346 | PXS4728A | |||||||
P2Y14R antagonist I-17 | 13422 | compound I-17 [PMID: 38874515] | |||||||
2-pyridylethylamine | 1197 | PEA | |||||||
Q | Back to top | ||||||||
QAV680 | 8996 | NVP-QAV680 | |||||||
quemliclustat | 10707 | AB-680, AB680 | |||||||
quilizumab | 8998 | 47H4 v5 hulgG1, MEMP1972A, RG-7449 | |||||||
QWF | 9568 | Boc-Gln-D-Trp(CH0)-Phe-OBzl, Nα-[Nα-[Nα-(tert-butyloxycabonyl)-L-glutaminyl]-N1-formyl-D-tryptophyl-L-phenylalanine benzyl ester | |||||||
R | Back to top | ||||||||
1R-11 | 10138 | ||||||||
R283 | 10049 | 1,3-Dimethyl-2[(oxopropyl)thio]imidazolium | |||||||
RA839 | 10487 | compound 7 [PMID: 31411465], RA-839 | |||||||
rabeximod | 9856 | Rob-803, Rob803 | |||||||
RANK ligand | 5066 | receptor activator of nuclear factor κB ligand, osteoclast differentiation factor (ODF), osteoprotegerin ligand, TNFSF11 | |||||||
ravulizumab | 10168 | ALXN-1210, ALXN1210, ravulizumab-cwvz, Ultomiris® | |||||||
rebastinib | 9173 | DCC 2036, DCC-2036, DP-1919 | |||||||
relatlimab | 9536 | BMS-986016, BMS986016, ONO-4482, Opdualag® (nivolumab + relatlimab-rmbw), relatlimab-rmbw | |||||||
remibrutinib | 10457 | compound 25 [PMID: 32083858], example 6 [WO2015079417A1], LOU-064, LOU064, LOU064-NXA, NVP-LOU064-NXA | |||||||
remtolumab | 9597 | A-1230717, ABT-122 | |||||||
reparixin | 8498 | DF 1681Y, repertaxin | |||||||
reproxalap | 10613 | ADX-102, ADX102, example 5 [WO2018039197A1], NS-2, NS2 | |||||||
resatorvid | 9036 | TAK-242, TAK242 | |||||||
resiquimod | 5051 | R-848, R848 | |||||||
reslizumab | 8091 | CDP-835, CDP835, Cinqaero®, Cinqair®, JES1-39D10, SCH55700 | |||||||
resolvin D1 | 3934 | RvD1, 7S,8R,17S‐trihydroxy‐4Z,9E,11E,13Z,15E,19Z‐docosahexaenoic acid | |||||||
resolvin D2 | 5417 | ||||||||
[3H]resolvin D1 | 4356 | [3H]-RvD1 | |||||||
resolvin E1 | 3333 | RvE1, 5S,12R,18R‐trihydroxy‐6Z,8E,10E,14Z,16E‐eicosapentaenoic acid | |||||||
[3H]resolvin E1 | 2901 | [(3)H]-labeled RvE1, [3H]RvE1 | |||||||
resveratrol | 8741 | 3,4',5-stilbenetriol, 3,5,4'-trihydroxystilbene, trans-resveratrol | |||||||
retifanlimab | 11583 | hPD-1 mAb 7(1.2), INCMGA0012, MGA012, retifanlimab-dlwr, Zynyz® | |||||||
revamilast | 9865 | Example 26 [WO2006064355A2], GRC 4039, GRC-4039, GRC4039 | |||||||
RG7112 | 9599 | ||||||||
rilapladib | 7376 | SB 659032 | |||||||
rilonacept | 6790 | Arcalyst®, IL-1 Trap, interleukin-1 Trap | |||||||
rilzabrutinib | 9993 | Example 31 [WO2014039899], PRN-1008, PRN1008 | |||||||
rimacalib | 9364 | SMP-114 | |||||||
rimexolone | 7099 | ORG-6216, Vexol® | |||||||
RIPA-56 | 9643 | compound 56 [PMID: 27992216], compound 92 [WO2016101885] | |||||||
RIPK2 inhibitor 3 | 10413 | compound 3 [PMID: 31265286], Example 1 [WO2014043446A1], GSK2983559 | |||||||
RIPK2 inhibitor 5 | 10419 | compound 5 [PMID: 31265286] | |||||||
RIPK2 inhibitor 8 | 9688 | ||||||||
RIPK3 inhibitor 18 | 10389 | ||||||||
RIPK3 inhibitor 42 | 10401 | ||||||||
risankizumab | 8922 | ABBV-066, BI 655066, BI-655066, risankizumab-rzaa, Skyrizi® | |||||||
ritlecitinib | 9559 | compound 11 [PMID: 28139931], example 5 [WO2015083028], Litfulo®, PF-06651600, PF06651600 | |||||||
rituximab | 6780 | HSDB 7455, IDEC-C2B8, MabThera®, Rituxan® | |||||||
Ro26-4550 | 5052 | Ro 26-4550, Ro-26-4550 | |||||||
rocatinlimab | 13045 | AMG-451, AMG451, KHK-4083, KHK4083 | |||||||
rocbrutinib | 12875 | ||||||||
rofecoxib | 2893 | Ceoxx®, MK 966, Vioxx® | |||||||
roflumilast | 6962 | ARQ-151/Zoryve® (roflumilast cream), BY-217, BYK-20869, Daliresp®, Daxas® | |||||||
roflupram | 10691 | FFPM, Zl-n-91 | |||||||
rolipram | 5260 | (±)-rolipram, (R,S)-rolipram | |||||||
ROMe | 6625 | (R)-FTY720 methyl ether, (R)-FTY720-OMe | |||||||
romiplostim | 6974 | MG531, Nplate® | |||||||
rontalizumab | 9640 | 9F3v13, RhuMAB IFNalpha, rhuMAb interferon-α | |||||||
RORC2 inverse agonist 66 [PMID: 30130103] | 10078 | example 5 [WO2016046755A1] | |||||||
rosiptor | 9249 | AQX-1125, AQX1125 | |||||||
rovazolac | 9625 | A-110, ALX-101, example 36 [WO2013130892] | |||||||
rovelizumab | 9598 | Hu23F2G, LeukArrest | |||||||
rozanolixizumab | 9801 | CA170_01519.g57 IgG4P, rozanolixizumab-noli, Rystiggo®, UCB-7665, UCB7665 | |||||||
RP-101075 | 9889 | ||||||||
RS-102895 | 779 | abaucin, RS102895 | |||||||
RS-504393 | 781 | RS 504393, RS504393 | |||||||
RSLV-132 | 10412 | RSLV132 | |||||||
rupatadine | 10103 | Rinialer®, Rupafin®, UR-12592, UR12592 | |||||||
ruxolitinib | 5688 | (R)-ruxolitinib, INC424, INCB 18424, INCB018424, Jakafi®, Jakavi® | |||||||
RV1729 | 10162 | RV-1729 | |||||||
RV6153 | 10163 | RV-6153 | |||||||
RvD1-ME | 5555 | RvD1-methyl ester | |||||||
RWJ-56423 | 9333 | (2S)-6 | |||||||
S | Back to top | ||||||||
S4-1 | 12321 | ||||||||
salbutamol | 558 | albuterol, SCH-13949W, Ventolin® | |||||||
salicylic acid | 4306 | Bazuka Extra Strength Gel®, salicylate | |||||||
salmeterol | 559 | GR 33343X, Serevent® | |||||||
salvianolic acid A | 13093 | Dan Phenolic Acid A, Danshen, Sal A | |||||||
Sanofi-14h | 13067 | compound 14h [PMID: 25589934] | |||||||
sapropterin | 5276 | Kuvan®, sapropterin dihydrochloride, SUN-0588, T-1401, tetrahydrobiopterin (THB) | |||||||
SAR-20347 | 9803 | ||||||||
sarilumab | 7999 | Kevzara®, REGN88, SAR153191 | |||||||
satralizumab | 9093 | Enspryng®, RG-6168, RG6168, SA-237, SA237, sapelizumab (deprecated INN), satralizumab-mwge | |||||||
SB202190 | 4307 | SB 202190, SB-202190 | |||||||
SB203580 | 5269 | PB 203580, RWJ 64809, SB-203580 | |||||||
SB 225002 | 833 | SB-225002, SB225002 | |||||||
SB290157 | 3529 | SB-290157 | |||||||
SB328437 | 3530 | SB 328437, SB-328437 | |||||||
SC-51089 | 1923 | SC 51089 | |||||||
SC-67655 | 8889 | ||||||||
Sch.336 | 9799 | analog 4j [PMID: 15664857], SCH-336, SCH336 | |||||||
SD-208 | 8246 | SCI-208, SD 208 | |||||||
S-26d [PMID: 37883692] | 12979 | ||||||||
secukinumab | 8078 | AIN 457, AIN457, Cosentyx®, NVP-AIN457 | |||||||
selectin P ligand | 10014 | ||||||||
seletalisib | 9800 | UCB 5857, UCB-5857, UCB5857 | |||||||
selinexor | 10036 | compound 70 [WO2013019561A1], KPT-330, KPT330, Nexpovio®, Xpovio® | |||||||
selnoflast | 12173 | Example 6 [WO2019008025A1], RG-6418, RG6418 | |||||||
selonsertib | 9040 | GS-4997 | |||||||
semaphorin 3A | 9902 | ||||||||
S-EMCA | 7048 | 6α-ethyl-23(S)-methyl-cholic acid, INT-777, INT777 | |||||||
serlopitant | 9280 | compound 17 (Jiang et al. 2009), VPD-737 | |||||||
setanaxib | 9932 | GKT-137831, GKT-831, GKT137831, GKT831 | |||||||
setipiprant | 10180 | ACT-129968, ACT129968, compound 28 [PMID: 23721423] | |||||||
setogepram | 10043 | 3-pentylbenzeneacetic acid, fezagepras, PBI-4050, PBI4050 | |||||||
SGC-CBP30 | 7529 | ||||||||
SIAIS178 | 10526 | compound 19 [PMID: 31539241], SIAIS-178 | |||||||
sibeprenlimab | 12102 | VIS-649, VIS649 | |||||||
sifalimumab | 8257 | MDX-1103, MEDI-545, MEDI545 | |||||||
siltuximab | 7396 | cLLB8, CNTO 328, Sylvant® | |||||||
sintilimab | 12990 | IBI 308, IBI-308, IBI308, Tyvyt® | |||||||
siponimod | 9289 | BAF-312, BAF312, compound 32 [PMID: 24900670], Mayzent® | |||||||
sirolimus | 6031 | AY-22989, Fyarro® (sirolimus albumin-bound particles), Rapamune®, rapamycin, WY-090217 | |||||||
SIRT1 activator 3 | 9514 | SA-3, SA3 | |||||||
sirukumab | 7989 | CNTO 136, CNTO-136, Plivensia (proposed trade name) | |||||||
SLM6071469 | 10641 | compound 10 [PMID: 31895563] | |||||||
SNG001 | 11129 | ||||||||
SNX0723 | 9260 | ||||||||
sofnobrutinib | 10094 | compound 4b [PMID: 30216722] | |||||||
solcitinib | 9697 | compound 1 [WO2010149771], GLPG-0778, GLPG0778, GSK2586184 | |||||||
sonelokimab | 10491 | IL17-MS3086, IL17MS3086, SEQ ID 836 [WO2012156219A1] | |||||||
sotrastaurin | 7946 | AEB-071, AEB071 | |||||||
sotuletinib | 8250 | BLZ 945, BLZ-945, BLZ945 | |||||||
SP-4206 | 9037 | compound 13 [PMID:12656598], SP4206 | |||||||
SP600125 | 5273 | 1,9-pyrazoloanthrone, JNK Inhibitor II, SP-600125 | |||||||
sparsentan | 8448 | DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors), BMS-346567, compound 7 [PMID 15634011], Filspari®, RE-021, retrophin | |||||||
spartalizumab | 10140 | NPV-PDR001, NPVPDR001, PDR-001, PDR001 | |||||||
spebrutinib | 7837 | AVL 292, AVL-292, cc-292 | |||||||
spesolimab | 12169 | BI-655130, BI655130, spesolimab-sbzo, Spevigo® | |||||||
sphingomyelin synthase 2 inhibitor 15w | 10054 | compound 15w [PMID: 30074791] | |||||||
SPRi3 | 10130 | example 23 [WO2011047156], SPR inhibitor 3 | |||||||
SR1001 | 10143 | SR-1001 | |||||||
SR144528 | 751 | SR 144528, SR-144528 | |||||||
SR1555 | 10145 | SR-1555 | |||||||
SR2211 | 10144 | SR-2211 | |||||||
SR2640 | 3329 | SR 2640, SR-2640 | |||||||
SR8185 | 9578 | SR-8185 | |||||||
18S-resolvin E1 | 5106 | 18S-RvE1 | |||||||
SRT1720 | 7703 | ||||||||
SRT2104 | 9515 | compound 4 [Ng et al., 2013], GSK2245840, SRT-2104 | |||||||
SS-208 | 10490 | compound 7b [PMID: 31414801], SS208 | |||||||
stem cell factor | 5055 | SCF, c-Kit ligand | |||||||
STING agonist 2 | 10127 | ||||||||
STING agonist 3 | 10128 | compound 3 [PMID: 30405246], diABZI, diABZI STING agonist-1 | |||||||
(R)-STU104 | 12006 | (R)-4e [PMID: 35442672] | |||||||
sulindac | 5425 | Clinoril® | |||||||
suprofen | 7298 | Profenal®, R-25061 | |||||||
sutimlimab | 9807 | BIVV009, Enjaymo®, IPN-009, IPN009, sutimlimab-jome, TNT009 | |||||||
SX682 | 10165 | ||||||||
Syk inhibitor | 6046 | K00564a, spleen tyrosine kinase inhibitor | |||||||
Syk inhibitor II | 6047 | K00592a | |||||||
SZM679 | 12311 | SZM-679 | |||||||
T | Back to top | ||||||||
T0901317 | 2755 | T 0901317, T-0901317 | |||||||
tabalumab | 8000 | LY 2127399, LY2127399 | |||||||
tadekinig alfa | 10077 | ||||||||
tafasitamab | 11131 | Minjuvi®, Monjuvi®, MOR-208, MOR00208, MOR208, tafasitamab-cxix, Xmab5574 | |||||||
TAK-632 | 10387 | compound 8B [PMID: 23906342], TAK632 | |||||||
TAK-715 | 9328 | compound 8h [PMID: 16162000], TAK 715, TAK0715 | |||||||
TAK-779 | 783 | TAK779 | |||||||
TAK-981 | 11305 | Example 133 [WO2016004136A1], I-263a [WO2016004136A1], subasumstat (proposed INN), TAK981 | |||||||
TAK-828F | 9867 | compound 10 [PMID: 29510038], TAK-828, TAK828F | |||||||
Takinib | 9655 | ||||||||
talabostat | 9892 | compound 1 [PMID: 18783201], PT-100, PT100, Val-boro-pro, Val-boroPro | |||||||
talmapimod | 7817 | SCIO 469 hydrochloride, SCIO-469 | |||||||
tamatinib | 5706 | R 406, R-406, R406 free base | |||||||
tanespimycin | 7751 | 17-AAG, 17-allylamino-17-demethoxygeldanamycin, 17-N-allylamino-17-demethoxygeldanamycin, 17AAG, compound 4 [PMID:15978816] | |||||||
tanzisertib | 9836 | CC-930, CC930, compound 1 [PMID: 22244937] | |||||||
tapinarof | 9686 | GSK-2894512, GSK2894512, Vtama®, WB-1001, WBI 1001, WBI-1001 | |||||||
TAS05567 | 9941 | ||||||||
tauroursodeoxycholic acid | 4746 | TUDA, Relyvrio® (sodium phenylbutyrate + taurursodiol), tauroursodeoxycholate, taurursodiol, TUDCA, UR 906, ursodoxicoltaurine (INN) | |||||||
TC14012 | 2902 | TC 14012, TC-14012 | |||||||
tebentafusp | 7378 | IMCgp100, Kimmtrak®, tebentafusp-tebn | |||||||
teduglutide | 7049 | ALX-0600, Gattex®, GLP2-2G, Revestive® | |||||||
telitacicept | 11827 | RC18, Tai'ai® | |||||||
telotristat ethyl | 9490 | LX-1606, LX1606, Xermelo® | |||||||
temelimab | 11530 | GNbAC1 | |||||||
tenalisib | 9907 | RP-6530, RP6530 | |||||||
teneligliptin | 9906 | compound 8g [PMID: 22959556], MP-513, MP513, Teneli | |||||||
tepilamide fumarate | 9770 | XP 23829, XP-23829, XP23829 | |||||||
teplizumab | 12252 | humanized OKT3, MGA031, PRV-031, teplizumab-mzwv, Tzield® | |||||||
tepoditamab | 10353 | MCLA-117, MCLA117, PB9122 | |||||||
TEPP-46 | 10555 | compound 46 [PMID: 20451379], ML-265, ML265, TEPP46 | |||||||
teprotumumab | 10612 | R1507, RG-1507, RG1507, RV 001, RV-001, Tepezza®, teprotumumab-trbw | |||||||
terfenadine | 2608 | RMI-9918, Seldane®, Triludan® | |||||||
teriflunomide | 6844 | A77 1726, Aubagio®, flucyamide, HMR-1726 | |||||||
tethered chemerin 9 | 9784 | ||||||||
tetomilast | 9877 | compound 19f [PMID: 7830278], OPC-6535, OPC6535 | |||||||
tezepelumab | 8933 | AMG 157, AMG-157, MEDI-9929, MEDI9929, tezepelumab-ekko, Tezspire® | |||||||
TG11-77 | 10603 | compound 20o [PMID: 31904232] | |||||||
TG6-129 | 9283 | ||||||||
TG8-260 | 12520 | compound 2f [PMID: 35187419], TG8260 | |||||||
TGFβ1 | 5060 | TGF-beta-1, transforming growth factor beta-1 | |||||||
TH5487 | 10184 | TH-5487 | |||||||
thalidomide | 7327 | K-17 | |||||||
theophylline | 413 | Nuelin®, Slo-Bid®, Theolair® | |||||||
thrombospondin 1 | 13047 | THBS-1, TSP-1, TSP1 | |||||||
thymic stromal lymphopoietin | 5083 | TSLP | |||||||
tibulizumab | 10350 | LY-3090106, LY3090106 | |||||||
tigemocoxib | 13505 | 29b-(S) [PMID: 20709553], SC-75416, SC75416 | |||||||
tildrakizumab | 8093 | Ilumetri®, Ilumya®, MK-3222, MK3222, SCH-900222, SCH900222, SUNPG1623, tildrakizumab-asmn | |||||||
timapiprant | 9277 | OC000459, OC459 | |||||||
timolumab | 9097 | 8c10, BTT-1023, BTT1023, r8c10, SI-3106, SI-636 | |||||||
tiotropium | 367 | BA-679-BR, Spiriva® | |||||||
tirabrutinib | 9265 | GS-4059, ONO-4059, ONO4059, Velexbru® | |||||||
tislelizumab | 9592 | Bai Zean®, BGB-A317, BGBA317, hu317-1/IgG4mt2, Tevimbra®, tislelizumab-jsgr | |||||||
TK05 | 9556 | ||||||||
TL6 | 5072 | activation-inducible TNF-related ligand, glucocorticoid- induced TNF-related ligand | |||||||
TL1A | 5071 | Tumor necrosis factor ligand superfamily member 15, membrane form | |||||||
TM30089 | 1905 | CAY 10471, CAY-10471, CAY10471 | |||||||
tocilizumab | 6881 | Actemra®, R-1569, RG-1569, RHPM-1, RoActemra® | |||||||
toddacoumalone | 13467 | compound 8 [PMID: 24597921] | |||||||
tofacitinib | 5677 | CP-690,550, CP-690550, tasocitinib, Xeljanz® | |||||||
tolebrutinib | 10625 | BTK'168, example 3 [WO2016196840A1], PRN-2246, PRN2246, SAR442168 | |||||||
tolmetin | 7311 | MCN-2559, McN-2559-21-98, Tolectin® | |||||||
tomaralimab | 9408 | OPN-305, OPN305, VK5A/H4 | |||||||
tomivosertib | 10167 | compound 23 [PMID: 29526098], eFT-508, eFT508 | |||||||
toreforant | 9276 | JNJ-38518168 | |||||||
toripalimab | 12989 | JS-001, JS001, Loqtorzi®, toripalimab-tpzi | |||||||
tositumomab | 6781 | Bexxar®, V10XA53 | |||||||
tozorakimab | 12964 | MEDI-3506, MEDI3506 | |||||||
tradipitant | 9278 | LY-686017, LY686017, VLY-686 | |||||||
tralokinumab | 8001 | Adbry®, Adtralza®, BAK1.1, CAT-354, tralokinumab-ldrm | |||||||
TRAM-34 | 2336 | ||||||||
tranilast | 6326 | MK-341, SB-252218 | |||||||
tregalizumab | 9864 | BT-061, hB-F5 | |||||||
tremelimumab | 8462 | CP-675, CP-675,206, CP-675206, Imjudo®, ticilimumab, tremelimumab-actl | |||||||
triamcinolone | 2870 | fluoxiprednisolone, Kenalog®, Nasacort® | |||||||
triamcinolone acetonide | 2867 | Zilretta® | |||||||
trifarotene | 9962 | Aklief®, CD5789, compound 15b [PMID: 29706423] | |||||||
trilaciclib | 9626 | Cosela®, G1T28 | |||||||
trilobatin | 13073 | phloretin-4'-O-glucoside, prunin dihydrochalcone | |||||||
tripelennamine | 7318 | Pyribenzamine® | |||||||
triple modulator 10 [PMID: 29878767] | 10002 | ||||||||
tryptanthrin 5i | 10126 | compound 5i [PMID: 24099220] | |||||||
tubastatin A | 9702 | ||||||||
TUG-1375 | 10107 | compound 31 [PMID: 30247908], TUG1375 | |||||||
tumour necrosis factor membrane form | 5073 | TNF membrane form, cachectin, necrosin, TNFα | |||||||
tumour necrosis factor shed form | 5074 | TNF shed form, cachectin, necrosin, TNF alpha soluble form, tumor necrosis factor soluble form | |||||||
TY-51469 | 9779 | ||||||||
TYK2 inhibitor 14l | 11425 | ||||||||
U | Back to top | ||||||||
U46619 | 1888 | 11α,9α-epoxymethano-PGH2, U 46619, U-46619 | |||||||
ublituximab | 8920 | Briumvi®, LFB-R603, TG-1101, TGTX-1101, ublituximab-xiiy | |||||||
ulinastatin | 10359 | Miraclid®, Ulinase®, Urinastatin® | |||||||
ulocuplumab | 9161 | BMS-936564, MDX-1338 | |||||||
umbralisib | 8916 | example A1 [US2014011819], RP-5264, RP5264, TGR-1202, TGR1202, Ukoniq® | |||||||
umeclidinium | 7354 | GSK573719A, Incruse Ellipta® | |||||||
UNC4203 | 10131 | MERTK inhibitor 19 [PMID: 30347155], UNC4203A [US20150291606A1] | |||||||
upadacitinib | 9246 | ABT-494, Rinvoq® | |||||||
uracil 20 | 9901 | ||||||||
urelumab | 9311 | BMS 663513, BMS-663513 | |||||||
usnoflast | 12883 | Example-6 [WO2020148619A1], ZY-IL1, ZYIL-1, ZYIL1 | |||||||
ustekinumab | 6885 | CNTO-1275, L04AC05, Stelara®, TT-20 | |||||||
utomilumab | 9244 | PF-05082566 | |||||||
V | Back to top | ||||||||
vactosertib | 8107 | EW-7197, EW7197, NOV-1301, TEW-7197 | |||||||
vadastuximab talirine | 9434 | SGN-CD33A | |||||||
valategrast | 11487 | R-411, RO-0272441 | |||||||
valdecoxib | 2894 | Bextra®, SC-65872 | |||||||
vamorolone | 9247 | Agamree®, VBP-15, VBP15 | |||||||
vanin-1 inhibitor [PMID: 33196323] | 11718 | example 1 [WO2016193844A1] | |||||||
varespladib | 9657 | compound 6m [PMID: 8978844], LY315920, S-5920, varespladib methyl (A-002), varespladib sodium (A-001) | |||||||
varokibart | 12187 | ||||||||
VCE-004.3 | 10030 | ||||||||
vecabrutinib | 10231 | BIIB-062, BIIB062, SNS-062, SNS062 | |||||||
vedolizumab | 7437 | Entyvio®, LDP-02, LDP02, MLN-0002, MLN-002, MLN002 | |||||||
velsecorat | 9325 | AZ13189620, AZD7594, compound 15m [PMID: 28937774] | |||||||
veltuzumab | 8268 | hA20, IMMU-106 | |||||||
vemurafenib | 5893 | PLX4032, RG7204, Zelboraf® | |||||||
venetoclax | 8318 | ABT-199, GDC-0199, Venclexta®, Venclyxto® | |||||||
vercirnon | 9046 | CCX282-B, GSK'786, GSK1605786, GSK1605786A, Traficet-EN | |||||||
verdiperstat | 10052 | AZD-3241, AZD3241 | |||||||
verlukast | 6193 | MK-679, MK679 | |||||||
vidofludimus | 9860 | 4SC-101, IMU-838 (vidofludimus calcium), SC12267 | |||||||
vidupiprant | 10169 | AMG 853, AMG-853, AMG853, compound 2 [PMID: 24900313] | |||||||
vilanterol | 7353 | GW642444X | |||||||
vimnerixin | 12100 | AZD-4721, AZD4721, compound 4 [WO2019055509A1], RIST4721 | |||||||
VIP | 1152 | ||||||||
vipadenant | 5612 | BIIB 014, BIIB014, V2006 | |||||||
vipoglanstat | 12209 | BI 1029539, BI-1029539, BI1029539, GS-248, GS248 | |||||||
vixarelimab | 13451 | KPL-716, KPL716 | |||||||
Vm24 | 10050 | α-KTx 23.1 | |||||||
vobarilizumab | 8363 | ALX-0061 | |||||||
voclosporin | 11388 | 1,11-anhydro[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl- N-methyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-methyl- 2-(methylamino)nona-6,8-dienoyl][(2S)-2-aminobutanoyl]- N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine], E-ISA247, ISA(TX)247, ISA-247, ISA247, ISATX247, Lupkynis®, R 1524, R-1524, R1524 | |||||||
vortioxetine | 7351 | Brintellix®, compound 5m [PMID: 21486038], Lu AA21004, Trintellix® | |||||||
VRT-043198 | 9034 | ||||||||
vunakizumab | 9296 | SHR-1314 | |||||||
VX-702 | 6059 | I14-1965, VX 702, VX702 | |||||||
W | Back to top | ||||||||
1400W | 5102 | W 1400 | |||||||
WH-4-023 | 8068 | ||||||||
WJYK50 | 10639 | compound 1c [PMID: 29649738] | |||||||
WKYMVm | 1048 | Trp-Lys-Tyr-Met-Val-[D]Met, WKYMVM | |||||||
WN1703 | 13463 | compound 16c [PMID: 28918097], WN-1703, XOR inhibitor 16c | |||||||
WRWWWW | 1040 | WRW4 | |||||||
WXFL10203614 | 12621 | WX614, WXFL-10203614 | |||||||
X | Back to top | ||||||||
XCL1 | 4447 | lymphotactin-α | |||||||
XCL1 | 3647 | c motif cytokine 1, cytokine SCM-1α, lymphotactin α | |||||||
XCL1 | 4446 | lymphotactin-α | |||||||
XCL2 | 4370 | C motif cytokine 2, lymphotactin β | |||||||
Xilonix TN | 8528 | ||||||||
Y | Back to top | ||||||||
YH35324 | 13448 | IgETRAP, YH-35324 | |||||||
YM90709 | 5090 | YM 90709, YM-90709 | |||||||
Z | Back to top | ||||||||
zabedosertib | 11415 | BAY-1834845, BAY1834845 | |||||||
zafirlukast | 3322 | Accolate®, ICI-204219 | |||||||
zaloglanstat | 11406 | ||||||||
zanubrutinib | 9861 | BGB-3111, BGB3111, Brukinsa®, compound 27b [US9447106] | |||||||
zasocitinib | 12155 | compound I-908 [US20190256519A1], NDI-034858, NDI034858, TAK-279, TAK279 | |||||||
zaurategrast | 11488 | CDP-323, CDP323 | |||||||
zelebrudomide | 13490 | compound 28 [PMID: 38300987], NX-2127, NX2127 | |||||||
zelnecirnon | 12893 | example 37 [WO2019147862A1], RPT-193, RPT193 | |||||||
zemprocitinib | 13221 | compound 1 [US20220009927] | |||||||
zenuzolac | 11682 | (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, GIT-027, GIT-27, GIT27, GLS-1027, GLS1027, rac-[(5R)-3-phenyl-4,5-dihydro-1,2-oxazol-5-yl]acetic acid, VGX-1027, VGX1027 | |||||||
zetomipzomib | 10409 | compound 12 [PMID: 30380863], KZR-616, KZR616 | |||||||
Z-FA-FMK | 11257 | MDL 201053, MDL-201053, MDL201053, Z-Phe-DL-Ala-fluoromethylketone, ZFA-fmk | |||||||
zigakibart | 12101 | BION-1301, BION1301, clone 14_1G.15 | |||||||
zileuton | 5297 | A-64077, ZYFLO® | |||||||
zilucoplan | 10404 | RA-101495, RA101495, Zilbrysq® | |||||||
zimberelimab | 12349 | AB-122, AB122, GLS-010 | |||||||
zimlovisertib | 9667 | compound 40 [PMID: 28498658], PF-06650833, PF06650833 | |||||||
(R)-ZINC-3573 | 9566 | ZINC-72453573 | |||||||
ziritaxestat | 9561 | compound 11 [PMID: 28414242], GLPG-1690, GLPG1690 | |||||||
ZK 756326 | 813 | ZK-756326, ZK756326 | |||||||
ZLN005 | 13255 | ZLN 005, ZLN-005 | |||||||
zomiradomide | 11904 | compound A [WO2022027058A1] | |||||||